Report on review of Quarterly Information - ITR

KPMG Auditores Independentes Rua Arquiteto Olavo Redig de Campos, 105, 6º andar - Torre A 04711-904 - São Paulo/SP - Brasil Caixa Postal 79518 - CEP 04707-970 - São Paulo/SP - Brasil Phone +55 (11) 3940-1500, Fax +55 (11) 3940-1501 www.kpmg.com.br Report on review of Quarterly Information - ITR To the Board of Directors and Stockholders Fleury S.A. São Paulo - SP Introduction We have reviewed the accompanying interim financial information, individual and consolidated, of Fleury S.A. ( The Company ), comprised in the Quarterly Information Form - ITR for the quarter ended September, comprising the balance sheet as of September and the respective statements of income and comprehensive income for the three and nine month period ended at that date and changes in equity and cash flows for the nine month period ended at that date, including the footnotes. Management is responsible for the preparation of the individual interim financial information in accordance with the Technical Pronouncement CPC 21(R1) - Interim Financial Information, and the consolidated interim financial information in accordance with CPC 21(R1) and the international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - IASB, such as for the presentation of these information in accordance with the standards issued by the Brazilian Securities Commission - CVM, applicable to the preparation of Quarterly Information - ITR. Our responsibility is to express a conclusion on these interim financial information based on our review. Review scope We conducted our review in accordance with the Brazilian and International standards on reviews of interim information (NBC TR 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for the financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the audit standards and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. KPMG Auditores Independentes, uma sociedade simples brasileira e firmamembro da rede KPMG de firmas-membro independentes e afiliadas à KPMG International Cooperative ( KPMG International ), uma entidade suíça. KPMG Auditores Independentes, a Brazilian entity and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ( KPMG International ), a Swiss entity. 1

Conclusion on interim financial information Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the Quarterly Information - ITR referred to above has not been prepared, in all material respects, in accordance with CPC 21(R1) and IAS 34 applicable to the preparation of Quarterly Information - ITR, and presented in accordance with the standards issued by the Brazilian Securities Commission - CVM. Others matters Interim statement of value added The interim financial information, individual and consolidated, related to statement of statements of value added (DVA), related to the nine month period ended September 30, 2018, prepared under the responsibility of the Company s management, presented as supplementary information under IAS 34, were subject to the same review procedure jointly with the Company s Quarterly Information ITR. To former our conclusion, we assess if these statements were reconciled with the interim final information and accounting records, as applicable, and if the form and information were according with criteria defined on Technical Pronouncement CPC 09 Statement of Valeu Added. Based on our review, nothing has come to our attention that causes us to believe that the statements of value added referred to above has not been prepared, in all material respects, in accordance with the individual and consolidated interim financial information taken as a whole São Paulo, October 25, 2018 KPMG Auditores Independentes CRC 2SP014428/O-6 (Original report in Portuguese signed by) Marcos Antonio Boscolo Accountant CRC 1SP198789/O-0 KPMG Auditores Independentes, uma sociedade simples brasileira e firmamembro da rede KPMG de firmas-membro independentes e afiliadas à KPMG International Cooperative ( KPMG International ), uma entidade suíça. KPMG Auditores Independentes, a Brazilian entity and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ( KPMG International ), a Swiss entity. 2

AND SUBSIDIARIES STATEMENT OF FINANCIAL POSITION (In thousands of Brazilian reais - R$) Note Parent Company Note Parent Company Assets 9/30/2018 12/31/2017 9/30/2018 31/12/2017 Liabilities and equity 9/30/2018 12/31/2017 9/30/2018 31/12/2017 Current assets Current liabilities Cash and cash equivalents 4 127.864 337.153 130.335 337.544 Financing 15 32.366 29.922 33.006 30.948 Marketable securities 5 721.747 334.031 759.434 334.286 Debentures 16 293.372 284.693 293.372 284.693 Derivative financial instruments 6 225 17 225 17 Finance lease 17 610 606 610 606 Trade receivables 7 541.899 502.823 550.611 512.241 Trade payables 18 157.554 146.851 162.032 148.485 Inventories 8 21.259 21.487 21.983 21.545 Payroll and related charges 19 135.606 99.744 137.758 100.354 Taxes recoverable 9 29.912 26.907 30.886 27.028 Taxes and contributions payable 20 23.941 29.878 24.875 30.575 IRPJ and CSLL to offset 38.325 22.228 38.851 22.258 IRPJ and CSLL payable 10.396-10.516 59 Receivables 11 4.752 3.854 4.752 3.854 Accounts payable - company acquisition 21 256 244 14.363 1.855 Receivables from related parties 25 1.004-98 - Dividends payable and interest on equity 22 41.420 22 41.420 Other assets 20.865 7.915 22.430 8.264 Other accounts payable 374 151 850 151 Total current asset 1.507.852 1.256.415 1.559.605 1.267.037 Total current liabilities 654.497 633.509 677.404 639.146 Noncurrent liabilities Noncurrent assets Financing 15 81.154 102.475 83.614 105.949 Credits receivable 11 3.528 12.694 3.528 12.694 Debentures 16 966.667 633.334 966.667 633.334 Dividends receivable - - 26 - Finance lease 17 6.354 6.769 6.354 6.769 Other assets 4.266 9.509 4.509 9.555 Deferred income tax and social contribution, net 22 388.317 364.793 386.196 362.777 Judicial deposits 10 48.232 47.419 48.365 47.521 Provision for tax, labor and civil risks 23 29.271 30.060 29.509 30.480 56.026 69.622 56.428 69.770 Taxes and contributions payable 20 28.990 28.200 30.242 29.549 Accounts payable - company acquisition 21 6.739 6.429 31.301 12.800 Total noncurrent liabilities 1.507.492 1.172.060 1.533.883 1.181.658 Equity Share capital 26a 1.416.603 1.413.608 1.416.603 1.413.608 Capital reserve - options granted recognized 24.077 17.923 24.077 17.923 Revaluation reserve - 78-78 Investments 12 143.814 47.167 12.397 11.296 Legal reserve 70.681 70.681 70.681 70.681 Property and equipment 13 680.329 633.304 705.266 641.920 Retained profit - 204.238-204.238 Intangible assets 14 1.501.165 1.505.589 1.604.788 1.537.309 Profit for the period 215.836-215.836 - Total noncurrent assets 2.381.334 2.255.682 2.378.879 2.260.295 Total equity 1.727.197 1.706.528 1.727.197 1.706.528 Total assets 3.889.186 3.512.097 3.938.484 3.527.332 Total liabilities and equity 3.889.186 3.512.097 3.938.484 3.527.332 - - - The notes are an integral part of the interim financial information

AND SUBSIDIARIES STATEMENT OF INCOME NINE-MONTH PERIODS ENDED SEPTEMBER (In thousands of Brazilian reais - R$, except earnings per share) Note Parent Company 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2017 to 9/30/2017 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2017 to 9/30/2017 Revenue from services rendered 28 662.134 612.021 1.960.138 1.790.789 683.036 615.586 2.009.709 1.800.965 Cost of services 29 (453.771) (419.373) (1.331.017) (1.209.679) (473.700) (422.373) (1.373.733) (1.218.450) Gross profit 208.363 192.648 629.121 581.110 209.336 193.213 635.976 582.515 Operating income (expenses) General and administrative 30 (71.955) (65.453) (214.318) (191.194) (72.020) (65.478) (215.915) (191.263) Other operating income (expenses), net 31 394 (1.239) (4.277) (7.029) (636) (1.244) (5.219) (7.034) Reversal (provision) for tax, labor and civil risks 23 (1.665) 992 (3.771) 530 (1.685) 992 (3.791) 530 Equity in the earnings (losses) of subsidiaries 12 (1.029) 780 1.279 2.417 295 376 817 1.108 Operating profit before financial result 134.108 127.728 408.034 385.834 135.290 127.859 411.868 385.856 Financial income 32 15.747 11.618 35.617 37.304 16.424 11.935 36.638 38.253 Financial expenses 32 (26.754) (22.893) (71.202) (78.446) (27.641) (23.091) (73.421) (79.027) Financial result (11.007) (11.275) (35.585) (41.142) (11.217) (11.156) (36.783) (40.774) Earnings before income tax and social contribution 123.101 116.453 372.449 344.692 124.073 116.703 375.085 345.082 Income tax and social contribution Current 22 (17.384) (3.866) (76.173) (34.095) (17.946) (4.052) (78.915) (34.632) Deferred 22 (15.376) (26.026) (22.874) (54.615) (15.786) (26.090) (22.768) (54.468) Net profit for the period 90.341 86.561 273.402 255.982 90.341 86.561 273.402 255.982 Earnings per share attributable to the Company's shareholders Basic earnings per share (weighted average) 33 0,29 0,29 0,87 0,81 0,29 0,29 0,87 0,81 Diluted earnings per share (weighted average) 33 0,28 0,27 0,85 0,79 0,28 0,27 0,85 0,79 The notes are an integral part of the interim financial information

AND SUBSIDIARIES STATEMENT OF COMPREHENSIVE INCOME NINE-MONTH PERIODS ENDED SEPTEMBER (In thousands of Brazilian reais - R$, except earnings per share) Parent Company 30/09/2018 30/09/2017 30/09/2018 30/09/2017 Net income for the period 273.402 255.982 273.402 255.982 Other comprehensive income Items that will be reclassified to profit (loss) in subsequent periods - - - - Items that will not be reclassified to profit (loss) in subsequent periods - - - - Total comprehensive income for the period 273.402 255.982 273.402 255.982 The notes are an integral part of the interim financial information

AND SUBSIDIARIES STATEMENT OF CHANGES IN EQUITY NINE-MONTH PERIODS ENDED SEPTEMBER (In thousands of Brazilian reais - R$) Share capital Capital reserve Note Share capital Share issue expenses Options granted recognized Revaluation reserve Legal reserve Retained earnings Profit for the period Additional dividends proposed Equity Balances on December 31, 2016 1.423.237 (22.784) 9.412 77 54.650 - - 71.133 1.535.725 Realization of revaluation reserve - - - 1 - - - - 1 Capital increase 8.396 - - - - - - - 8.396 Stock option plan 27 - - 6.226 - - - - - 6.226 Net income for the period (R$0.81 per share) - - - - - - 255.982-255.982 Dividends and interest on equity - - - - - - (58.941) (71.133) (130.074) Balances on September 30, 2017 1.431.633 (22.784) 15.638 78 54.650-197.041-1.676.256 Balances on December 31, 2017 1.436.392 (22.784) 17.923 78 70.681 204.238 - - 1.706.528 Capital increase 2.995 - - - - - - - 2.995 Stock option plan 27 - - 6.154 - - - - - 6.154 Net income for the period (R$0.87 per share) - - - - - - 273.402-273.402 Dividends paid - - - - - (204.238) - - (204.238) Interest on equity - - - - - - (57.566) - (57.566) Asset revaluation - - - (78) - - - - (78) - Balances on September 1.439.387 (22.784) 24.077-70.681-215.836-1.727.197 The notes are an integral part of the interim financial information

AND SUBSIDIARIES STATEMENT OF CASH FLOWS NINE-MONTH PERIODS ENDED SEPTEMBER (In thousands of Brazilian reais - R$) Note Parent Company 9/30/2018 9/30/2017 9/30/2018 9/30/2017 Net profit 273.402 255.982 273.402 255.982 Items not affecting cash: Income tax and social contribution 22 99.047 88.710 101.683 89.100 Financial income and expenses 51.224 45.566 55.020 44.066 Depreciation and amortization 29 e 30 131.804 102.815 135.227 103.273 Equity in the earnings (losses) of subsidiaries 12 (1.279) (2.417) (817) (1.108) Stock option plan 27 6.154 6.226 6.154 6.226 Creation of provision for tax, labor and civil risks 23 69 (530) 69 (530) Estimated losses with disallowances and doubtful accounts 7 30.590 34.471 30.638 34.433 Profit sharing 23.365 21.817 23.365 21.817 Other 2.154 1.602 2.257 2.130 Cash flow from operating activities before changes in assets and liabilities 616.530 554.242 626.998 555.389 (Increase) in accounts receivable 7 (69.423) (116.891) (68.423) (117.122) (Increase) decrease in inventories 8 229 7.806 (438) 7.806 (Increase) decrease in taxes recoverable 9 (19.102) 10.135 (20.471) 10.468 (Increase) in judicial deposits 10 (813) (6.362) (843) (6.359) (Increase) decrease in other assets (1.446) 9.111 (1.446) 9.112 Increase (decrease) in trade payables 18 10.846 (5.686) 13.547 (5.611) Increase (decrease) in payroll and related charges payable 19 12.404 (2.710) 14.039 (2.710) Increase (decrease) in tax liabilities 20 6.420 775 6.126 (104) (Decrease) in taxes paid in installments (10.954) (2.644) (11.125) (2.644) (Decrease) in other liabilities (784) (441) (483) (508) Total changes in assets and liabilities (72.623) (106.907) (69.517) (107.672) Income tax and social contribution paid (65.777) (29.466) (68.145) (29.865) Net cash from operating activities 478.130 417.869 489.336 417.852 Acquisition of property and equipment and intangible assets 13 e 14 (177.019) (194.469) (183.385) (194.469) Sale of property and equipment 1.428-1.428 - Marketable securities - funding and earnings 5 (387.715) (91.846) (425.148) (93.912) Marketable securities - redemptions 5-16.531-17.147 Payment of acquired companies less cash and cash equivalents - (585) (39.829) (585) Payment of dividends 2.1 d - - (17.500) - Increase in related parties (advance for future capital increase) (1.481) - 129 - Acquisition of interest (1.387) (1.387) Capital contribution in subsidiary (92.500) - - Income from financial investments (classified as cash) 32 10.515 23.771 10.651 24.673 Net cash used in investing activities (648.159) (246.598) (655.041) (247.146) Funding of financing/debentures 16 500.000 50.203 500.000 50.203 Settlement (principal) of financing and debentures 15 e 16 (189.443) (15.642) (190.844) (15.642) Interest paid in financing and debentures 15 e 16 (50.159) (80.932) (50.261) (80.932) Financial fees and others 32 (2.726) (2.915) (2.727) (2.915) Derivative financial instruments (417) (605) (417) (605) Capital increase 26 2.995 8.396 2.995 8.396 Dividends and/or interest on equity 26 (303.210) (130.071) (303.210) (130.071) Related parties (56) 26 (56) 26 Other receivables from related parties - Note Debt - - (550) - Confirming operation 3.756-3.756 - Net cash used in financing activities (39.260) (171.540) (41.314) (171.540) Decrease in cash and cash equivalents (209.289) (269) (207.019) (834) Cash and cash equivalents At the beginning of the period 4 337.153 310.500 337.354 313.834 At the end of the period 4 127.864 310.231 130.335 313.000 Changes in cash and cash equivalents (209.289) (269) (207.019) (834) The notes are an integral part of the interim financial information

AND SUBSIDIARIES STATEMENT OF VALUE ADDED NINE-MONTH PERIODS ENDED SEPTEMBER (In thousands of Brazilian reais - R$) Parent Company 9/30/2018 9/30/2017 9/30/2018 9/30/2017 Reclassified Reclassified Revenue 2.095.687 1.911.367 2.149.369 1.922.151 Revenue from services rendered 2.118.681 1.945.140 2.172.230 1.955.886 Estimated losses with disallowances and doubtful accounts (30.590) (34.471) (30.638) (34.433) Other revenue 7.596 698 7.777 698 Input acquired from third parties (740.256) (688.649) (770.219) (697.031) Cost of services (683.486) (638.454) (712.521) (646.766) Materials, electricity, outsourced services and others (55.821) (49.290) (56.749) (49.360) Loss/recovery of asset values (949) (905) (949) (905) Gross value added 1.355.431 1.222.718 1.379.150 1.225.120 Depreciation and amortization (131.804) (102.817) (135.227) (103.275) Net value added 1.223.627 1.119.901 1.243.923 1.121.845 Value added received through transfer 38.565 41.525 39.193 41.181 Equity in the earnings (losses) of subsidiaries 1.279 2.417 817 1.108 Financial income 37.286 39.108 38.376 40.073 Total value added to distribute 1.262.192 1.161.426 1.283.116 1.163.026 Distribution of value added (1.262.192) (1.161.426) (1.283.116) (1.163.026) Personnel and charges (463.203) (424.693) (470.918) (424.693) Direct compensation (317.677) (288.557) (323.681) (288.557) Benefits (118.375) (112.251) (119.424) (112.251) Charges (27.151) (23.885) (27.813) (23.885) Taxes, fees and contribution (320.737) (293.602) (329.152) (294.615) Federal (257.363) (237.725) (263.702) (238.523) Municipal (63.374) (55.877) (65.450) (56.092) Interest, rental and other operating expenses (204.850) (187.149) (209.644) (187.736) Rental (117.010) (98.943) (118.360) (98.943) Interest (71.202) (78.446) (73.421) (79.028) Other operating expenses (16.638) (9.760) (17.863) (9.765) Interest on equity (57.566) (58.941) (57.566) (58.941) Retained earnings (215.836) (197.041) (215.836) (197.041) The notes are an integral part of the interim financial information

Earnings 3Q18 Conference call: October 26 th 11AM (10AM EDT) Phone: Brazil: + 55 11 2188-0155 USA:+1 646-843-6054 Replay: +55 11 2188-0400 Code: Fleury Webcast: www.fleury.com.br/ri In September 28 th, 2018: Total shares 315,654,796 Market cap R$ 6,989MM US$ 1,745MM Share price R$ 22.14 /US$ 5.53 Fleury ON B3: FLRY3 Bloomberg: FLRY3 BZ Thomson Reuters: FLRY3-BR Debentures BRFLRYDBS015 BRFLRYDBS023 BRFLRYDBS031 BRFLRYDBS049 BRFLRYDBS056 GrupoFleury Investor Relations www.fleury.com.br/ir ri@grupofleury.com.br +55 11 5014-7413

Earnings 3Q18 São Paulo, October 25 th, 2018 Grupo Fleury announces today its 3 rd quarter 2018 (3Q18) results. All figures are compared to the same period of the previous year, unless otherwise stated, and are rounded to the nearest thousand, but may have differences when compared to the financial statements due to decimal digits. Highlights Net Revenue of R$ 683.0 million (+11.0%). Same Store Sales growth of 6.8% in PSCs 2. Cancellations represented 1.5% (improvement of 14 bps). EBITDA of R$ 181.5 million (+11,1%), with margin of 26.6% (stable). Net Income of R$ 90.3 million (+4.4%). Operating Cash Flow of R$ 173.5 million (+1.7%). Return on Invested Capital (ROIC 1 ), excluding goodwill, reached 41.3% (-238 bps). NPS reached 77.9% (+93 bps). Launch of 6 new a+ brand PSCs in São Paulo. 55% of the Expansion Plan s new area is in initial stage of maturation with under 12 months of operation. ¹ Excludes the goodwill of the stockholder s equity. ² Patient Service Centers. Financial Indicators Financial Indicators (R$ MM) 3Q18 3Q17 Variation 9M 2018 9M 2017 Variation Gross Revenue 738.5 667.7 10.6% 2,172.8 1,956.3 11.1% Net Revenue 683.0 615.6 11.0% 2,009.7 1,801.0 11.6% Gross Profit 209.3 193.2 8.3% 636.0 582.5 9.2% EBITDA 181.5 163.4 11.1% 546.3 488.0 11.9% Net Income 90.3 86.6 4.4% 273.4 256.0 6.8% Net Cash Income 1 106.1 112.7-5.8% 296.2 310.5-4.6% Operating Cash Flow 173.5 170.5 1.7% 489.3 417.8 17.1% Cancellations (% Gross Revenue) -1.5% -1.7% 14.0 bps -1.4% -1.8% 33 bps Gross Margin % 30.6% 31.4% -74.0 bps 31.6% 32.3% -70 bps EBITDA Margin % 26.6% 26.5% 3.0 bps 27.2% 27.1% 8 bps Effective Tax Rate -27.2% -25.8% -136.0 bps -27.1% -25.8% -129 bps Net Income Margin % 13.2% 14.1% -84.0 bps 13.6% 14.2% -61 bps Net Cash Income / Net Revenue 15.5% 18.3% -276.0 bps 14.7% 17.2% -250 bps Operating Cash Flow / Net Revenue 95.6% 104.4% -877.0 bps 89.6% 85.6% 396 bps ROE (LTM) 19.9% 19.2% 66.0 bps 19.9% 19.2% 66 bps ROIC (LTM) 15.4% 14.9% 49.0 bps 15.4% 14.9% 49 bps ROIC without goodwill (LTM) 41.3% 43.6% -238.0 bps 41.3% 43.6% -238 bps ¹ Net Cash Income : excludes the impact of deferred income tax 1

Management Comments We continued with the execution of our Expansion Plan, adding 6 a+ brand PSCs in São Paulo this quarter. This expansion of our network occurred with the opening in July of 3 PSCs, all fast sites, offering clinical analysis and ultrasonography in the regions of Jardins, Vila Andrade and Alphaville. In August, we inaugurated the a+ Granja Viana PSC, a fast site unit with clinical analysis offering, marking our entrance in the extreme west of São Paulo city. Also, this month, we inaugurated the PSC a+ Tatuapé, a large PSC, with a complete mix of tests, including 2 MRIs and 1 CT scan. Lastly, in September, we inaugurated the São Bernardo do Campo fast site PSC, the second PSC in this region, to meet the growing demand for our clinical analysis and ultrasound services. In the personalized and precision medicine segment, we developed internally, through our R&D, 16 new tests for genomics, among these we highlight 3 new tests for diabetes that represents an important advance for a better diagnosis of more rare and genetic types. Currently we have a portfolio of 287 tests for genomics, which puts us ahead in this segment. In 9M18, genomics revenues grew by 51%. We have started an unprecedented research in Brazil, in partnership with Pérola Byinton Hospital and the american company, Genomic Health, to advance the treatment of breast cancer through the genomic test Oncotype. The expectation is that in more than 70% of the cases of the studied patients there is no need for treatment through chemotherapy, which could result in a strong reduction, around 30%, in the cost of treatment and delivery a relevant benefit for the patients, increasing the chances of treatment and reducing side effects. Still in the personalized and precision medicine segment, we concluded in 3Q18 the negotiation of accreditation with 2 healthcare operators of a relevant part of our portfolio of genomics tests. These are important movements and connected with our strategy of strong growth in the genomics segment in the coming years, gaining relevance in our revenues. At the same time, we have intensified our digital transformation, with the objective of improving the client's journey in the use of our services, as well as further streamlining our internal management and efficiency processes. In this context, the Digital Check-In Project is already implemented in 10 PSCs in São Paulo, 6 of the a+ brand and 4 of the Fleury brand. In the coming quarters we expect to accelerate the roll out of this project. Our actions in digital transformation and innovation were once again recognized through Valor Inovação Brasil award, from the Valor Econômico newspaper. In this edition, the highlight was our platform of genomic tests, in addition to projects with the use of Artificial Intelligence. We also received a recognition from the Cancer Institute of the State of São Paulo (ICESP), with the first place in the Oncology Research category with the TOT genomic test, indicated to identify metastatic tumors of unknown origin. An important award was also granted by Center for Communication Studies (CECOM), which recognized the company among the companies that best communicate with journalists, being the only mention in the segment of healthcare service providers. Finally, we were in fifth place among 185 companies with shares traded on B3 in the Broadcast Empresas award, after evaluating several financial indicators. These advances and acknowledgments contributed to further increase of the Customer Satisfaction, as measured by the Net Promoter Score (NPS), which reached 77.9% in the quarter, an increase of 93 bps compared to 3Q17, highlighted by the operations of a+ brand in Paraná, Felippe Mattoso brand and Labs a+ brand both in Rio de Janeiro and a+ brand in Pernambuco. The 3Q18 result showed growth of 10.6% in Gross Revenue and 11.0% in Net Revenue. EBITDA increased by 11.1% to R$ 181.5 million, with a EBITDA margin of 26.6%. Net Income increased by 4.4%, to R$ 90.3 million. We faced in the quarter the seasonal effect caused by the World Cup event in the first fortnight of July, which impacted our operations, reducing customer flow in the month. Despite this effect, we observed a consistent growth in the Regional Brands, mainly in the a+ brands in São Paulo, Labs a+ and Felippe Mattoso brands, both in Rio de Janeiro. 2

It is also worth noting that, in view of the economic scenario, the premium segment has shown a variation in the number of beneficiaries in recent quarters, having this effect reflected in the performance of the Fleury brand. Even in the face of this scenario, we understand that the brand has expanded its market share in the premium segment, mainly because of its competitive power, an attribute that protects it more from the negative effects imposed by this context. For the next few quarters, we continue working to capture the growth opportunities and efficiency gains in our portfolio of brands, either through organic expansion through the Expansion Plan, whose focus in the short term is on Regional Brands, or on the Fleury brand, increasing the occupation of existing assets by capturing new customers and offering new products and services, in a design of a differentiated healthcare platform. Therefore, the company will continue to apply its skills - technical, medical, service and management excellence - to implement a strategy of leadership in the healthcare sector, with a focus on integrated patient care and the generation of value for the whole healthcare chain and its shareholders. 3

Financial Performance Gross Revenue Revenue reached R$ 738.5 million in the quarter, growth of 10.6%. The expansion of Regional Brands excluding Rio de Janeiro (+33.0%) and brands of Rio de Janeiro (+17.3%) was noteworthy. Disregarding the PSCs from the acquisitions of Serdil and IRN, consolidated as of 1Q18 and 2Q18, respectively, Gross Revenue in the quarter showed an organic growth of 7.9%. Highlights for Regional Brands excluding Rio de Janeiro (+18.3%) and Rio de Janeiro Brands (+17.3%). In 9M18, Gross Revenue increased by 11.1%. The increase in Regional Brands excluding Rio de Janeiro (+30.4%) and Rio de Janeiro Brands (+14.1%) was noteworthy. Similarly, PSCs from the Serdil and IRN acquisitions, consolidated as of 1Q18 and 2Q18, respectively, Gross Revenue in 9M18 posted an organic growth of 9.0%. Highlights for Regional Brands excluding Rio de Janeiro (+18.6%) and Rio de Janeiro Brands (+14.1%). Gross Revenue (R$ MM) +10.6% 738.5 667.7 Gross Revenue (R$ MM) 1,956.3 +11.1% 2,172.8 3Q17 3Q18 9M 2017 9M 2018 Business Line Performance 3Q18 vs. 3Q17 Grupo Fleury 7.9% 2.7% 10.6% Grupo Fleury Business line performance 9M 2018 vs. 9M 2017 9.0% 2.1% 11.1% 1.1 PSCs 8.0% 3.2% 11.3% 1.1 PSCs 9.0% 2.5% 11.5% 1.1.1 Fleury brand 1.1% 1.1.1 Fleury brand 3.9% 1.1.2 Regional brands excl. RJ 18.3% 14.7% 33.0% 1.1.2 Regional brands excl. RJ 18.6% 11.8% 30.4% 1.1.3 Regional brands RJ 17.3% 1.1.3 Regional brands RJ 14.1% 1.2 Operations in Hospitals 7.8% 1.2 Operations in Hospitals 9.1% Effect of Serdil and IRN acquisitions Effect of Serdil and IRN acquisitions Business Portfolio Business Portfolio 16.5% 16.2% 16.0% 17.1% 16.2% 16.3% 15.9% 16.8% 18.3% 22.0% 17.9% 21.0% 49.0% 44.8% 49.6% 46.4% 3Q17 3Q18 9M 2017 9M 2018 B2B Regional brands RJ Regional brands excl. RJ Fleury brand B2B Regional brands RJ Regional brands excl. RJ Fleury brand 4

Gross Revenue and Asset Efficiency from Patient Service Center (PSC s) The Gross Revenue of PSCs reached R$ 620.1 million in 3Q18, an increase of 11.3%. Excluding the PSCs from the acquisitions of Serdil and IRN, consolidated as of 1Q18 and 2Q18, respectively, Gross Revenue of the PSCs in the quarter showed an organic growth of 8.0%. In 9M18, Gross Revenue from PSCs reached R$ 1.8 billion, an increase of 11.5%. Similarly, without considering the PSCs coming from the acquisitions of Serdil and IRN, consolidated as of 1Q18 and 2Q18, respectively, the Gross Revenue of the PSCs in 9M18 presented an organic growth of 9.0%. The efficiency indicators, measured by Gross Revenue per sqm and number of PSCs, reflect the Expansion Plan, which added a significant service area to our portfolio of brands. The new PSCs are advancing in the maturation curves established in our planning to reach the potential of revenue and profitability. In 3Q18, asset efficiency measured by the Gross Revenue per square meter decreased by 1.7% compared to the same period of 2017, while the efficiency of the Gross Revenue per PSC decreased by 1.9%, reaching R$ 3.5 million per PSC in the quarter. Gross Revenue per m² Gross Revenue per PSC (R$ MM) 5.0 4.8 5.4 5.2 5.2 4.8-1.7% 5.3 5.2 5.1 3.6-1.9% 3.5 100.2 100.5 100.8 103.2 106.9 110.2 113.2 118.4 120.9 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 PSCs Quarterly Average Gross Revenue per m² (R$ thousand) Thousands m² PSCs 3Q17 3Q18 Since the announcement of our Expansion Plan in the last quarter of 2016 through September/18, we have inaugurated 44 PSCs, corresponding to a gross increase of 15.7 thousand square meters of patient service area. Of this area, 55% were inaugurated less than 12 months ago, which means that most of these PSCs are still in the early stage of the maturation curve. In addition to the PSCs inaugurated by the Expansion Plan, we added 5 new PSCs through acquisitions, of which 1 in the Serdil brand (Porto Alegre) and 4 in the IRN brand (Natal), representing 4,800 square meters of service area. Patient Service area - Expansion plan (m² thousand) 3.4 (21%) 0.6 (4%) 1.6 (10%) 3.0 (19%) 15.7 (100%) 7.1 (45%) 55% launched in the last 12 months >12 months 9 to 12 months 6 to 9 months 3 to 6 months <3 months Total 5

Gross Revenue per Test The Gross Revenue per Test for the Fleury Group presented a growth of 1.7% in the quarter. This growth reflects the mix of tests, brands and segments carried out in the period, as well as the new price table resulting from the annual readjustment. In 9M18, growth was 1.8%. PSC s: Gross Revenue per test increased by 0.7% in the quarter and 0.7% in 9M18. The observed growth stems from the mix of tests and brands, as well as the annual price readjustment that reflects the lower level of inflation, significantly below the comparison with the previous year; Hospital Operations: Gross Revenue per test recorded growth of 1.5% in the quarter and 2.2% in 9M18. The increase is a result of the process of maturation of the mix of tests of the new hospital operations, which has been observed in the previous quarters; Lab-to-Lab: presented a reduction of 2.4% in the quarter and 4.1% in 9M18. Gross Revenue per test 3Q18 3Q17 Variation 9M 2018 9M 2017 Variation Grupo Fleury 38.0 37.4 1.7% 38.3 37.6 1.8% - Patient Service Centers 54.5 54.1 0.7% 54.9 54.5 0.7% - Hospital Operations 14.0 13.8 1.5% 14.0 13.7 2.2% - Lab to Lab 36.4 37.3-2.4% 35.1 36.6-4.1% Gross Revenue from PSCs In 3Q18, PSC s grew 11.3% and 8.0% excluding PSCs from acquisitions. In the period Same Store Sales (SSS) increased 6.8%. In the quarter, we had a calendar impacted by the World Cup in the first half of July, as well as a business day less in the state of São Paulo due to holiday. In 9M18, the PSC s grew 11.5% and 9.0%, excluding PSCs from acquisitions. Fleury Brand Fleury's gross revenue grew 1.1% in the quarter and 3.9% in 9M18. Given the economic scenario, the premium segment has shown a variation in the number of beneficiaries in the last quarters, this effect has reflected in the performance of the Fleury brand. Even in view of this scenario, we understand that the brand has expanded its market share in the premium segment, mainly in the regions where we launched new PSCs. In addition to the most relevant effect cited above, we had a combination of punctual effects with the World Cup event, weaker calendar due a holyday, maintenance and replacements of imaging equipment that affected our growth. We continue to develop new product and service offerings that should broaden our participation in the healthcare market and increase the occupancy of existing assets, as well as capture new customers in the current product and service offerings, in a design of a differentiated healthcare platform. Regional Brands excluding Rio de Janeiro The Gross Revenue of the Regional Brands, excluding Rio de Janeiro, increased by 33.0% (+18.3% organic), mainly due to the increase in Gross Revenue in the a+ brand in São Paulo (+29.5%),, where all growth is organic; Rio Grande do Sul (+20.4%), resulting from the acquisition of Serdil brand, consolidated in 1Q18; and Northeast region (+58.1%), due to the acquisition of IRN brand, consolidated in 2Q18. In 9M18, growth was 30.4% and 18.6% excluding acquisitions. The strong growth of Regional Brands is explained, for the most part, by: (i) increase in the number of services, (ii) expansion of the offer with the inauguration of the new units and expansion of routes in mobile attendance services, (iii) relationship with physicians based on medical knowledge exchanged, and (iv) increasing recognition of our brands by physicians and clients. 6

In the 12-month period ended September/18, 14 units were added to the revenue increase, 8 fast-site units, 4 medium-sized units and 2 large units. In the quarter, 6 a+ brand units were inaugurated in São Paulo and 5 a+ brand units were closed in Bahia. The closures in Bahia are part of the action plan to generate better efficiency in the assets of this region. Rio de Janeiro Brands The Gross Revenue of Rio de Janeiro Brands grew 17.3% in the quarter and 14.1% in 9M18. The strong growth is the result of a number of factors, among which we have listed: (i) increased attendance in clinical analyzes, (ii) expansion and optimization of the offer with an expanded scheduling for image tests, (iii) accreditation of new operators initiated since 4Q of the previous year, (iv) expansion of mobile attendance services routes, (v) relationship with physicians based on medical knowledge exchanged, and (vi) increase of penetration in the current healthcare operators portfolio. In the accumulated 12 months, ended in September/18, contributed to the increase of revenue 5 new PSCs Labs a+ and 1 PSC Felippe Mattoso, all fast sites. Gross Revenue Indicators 3Q18 vs. 3Q17 Fleury Brand Regional Brands excl. RJ Brands RJ Total (PSCs) Indicators - Gross Revenue 1.1% 33.0% 17.3% 11.3% - SSS -1.2% 9.3% 15.1% 6.8% - Gross Revenue / m 2* -1.4% -3.9% 13.4% -1.7% - Gross Revenue / PSC* -4.6% 18.2% 4.8% -1.9% * The Gross Revenue per sqm and Gross Revenue per PSC indicators are impacted by the Expansion Plan since the new PSCs are at the beginning of the maturation curve. Gross Revenue from B2B Hospital Operations The Gross Revenue from Operations in Hospitals reached R$ 108.1 million in the quarter, an increase of 7.8%. Growth in Same Hospital Sales (SHS) was 4.2% over the same period. In 9M18, Gross Revenue increased by 9.1%. Lab-to-lab Gross Revenue was R$ 8.8 million in the quarter, an increase of 6.9%. In 9M18, Gross Revenue increased by 10.4%. Preventive medicine Gross Revenue reached R$ 1.4 million in the quarter and R$ 4.0 million in 9M18. 7

Revenue Tax and Cancellations/Deductions Taxes on Gross Revenue represented 6.1% in the quarter, a stable percentage compared to the same period in 2017. In the quarter, the cancellations and deductions accounted for 1.5% of gross revenue, R$ -11.3 million, and improved by 14 bps compared to 3Q17. In 9M18, the glosses and rebates indicator totaled 1.4% of gross revenue, R$ -31.5 million, and improved 33 bps compared to the same period of the previous year. The result reflects the continuous improvement of processes and systems related to the receiving cycle. Since 1Q18, the accounting standard CPC 48 was enforced, which, among other requirements, has impacted the Company with a new classification of the estimated losses with bad debt. Until 2017, the classification of these losses was carried out as a reduction of gross revenue and was recognized as Other Operating Expenses (Notes 2.1 - letter "e" and 31). On a managerial basis, we continue to report the percentage of cancellations and deductions including the estimated losses with bad debt. Deduction + Cancellation/Gross Revenue and Deduction and Cancellation (R$ MM) - 14 bps 1.7% (-11.1) 1.5% (-11.3) Deduction + Cancellation/Gross Revenue and Deduction and Cancellation (R$ MM) 1.8% (-34.9) -33 bps 1.4% (-31.5) 3Q17 3Q18 9M 2017 9M 2018 Net Revenue Net Revenue totaled R$ 683.0 million in the quarter, growth of 11.0%. In 9M18, the increase was 11.6%. Net Revenue (R$ MM) +11.0% 683.0 615.6 Net Revenue (R$ MM) +11.6% 2,009.7 1,801.0 3Q17 3Q18 9M 2017 9M 2018 8

Cost of Services Cost of Services in 3Q18 amounted to R$ 473.7 million, a growth of 12.2%. In relation to Net Revenue, costs represented 69.4%, an increase of 74 bps compared to the same period of the previous year. In 9M18, there was a 12.7% growth, with a 70 bps increase in relation to Net Revenue. Cost of Services breakdown R$ MM 3Q18 3Q17 Variation % Net Revenue R$ MM % Net Revenue % bps Personnel and medical services 234.1 34.3% 218.9 35.6% 7.0% -128 bps General services, rentals and utilities 135.0 19.8% 116.0 18.9% 16.3% 91 bps Materials and Test Intermediation 68.7 10.1% 59.9 9.7% 14.7% 33 bps Depreciation and Amortization 34.1 5.0% 25.3 4.1% 34.8% 88 bps General Expenses 1.9 0.3% 2.3 0.4% -18.2% -10 bps Cost of Services 473.7 69.4% 422.4 68.6% 12.2% 74 bps Cost of Services breakdown R$ MM 9M 2018 9M 2017 Variation % Net Revenue R$ MM % Net Revenue % bps Personnel and medical services 688.3 34.3% 623.1 34.6% 10.5% -35 bps General services, rentals and utilities 389.0 19.4% 339.4 18.8% 14.6% 51 bps Materials and Exam Intermediation 192.9 9.6% 177.7 9.9% 8.5% -27 bps Depreciation and Amortization 98.0 4.9% 71.6 4.0% 37.0% 90 bps General Expenses 5.5 0.3% 6.7 0.4% -18.2% -10 bps Cost of Services 1,373.7 68.4% 1,218.4 67.7% 12.7% 70 bps As below, the analysis of the main Cost of Service in 3Q18 compared to 3Q17: Personnel and Medical Services (+7.0%) are the main cost of the company and accounted for 34.3% of Net Revenue, a reduction of 128 bps. The efficiency gain of this line is related to: (i) reduction of costs with our employees' health plans, with more efficient management and usage of this resource; and (ii) with salaries, in which we presented growth of only 6.5% of the headcount, as well as a readjustment of about 1.7% as a result of collective bargaining as of May/18. General Services, Rentals and Utilities (+16.3%) corresponded to 19.8% of Net Revenue, an increase of 91 bps, impacted by the rental of equipment in the central lab, due to the new model of contracting of one of our materials suppliers, and increased costs with electricity according to seasonal rate adjustment. Materials and Tests Intermediation (+14.7%) accounted for 10.1% of Net Revenue, an increase of 33 bps. The increase in the relation with Net Revenue is associated with the growth in the volume of tests sent to reference international laboratories, whose the cost matrix is more concentrated in this line. Depreciation and Amortization (+34.8%) amounted to 5.0% of Net Revenue, an increase of 88 bps in comparison with the previous period. The growth is the result of the Company's Expansion Plan with an increase in property, plant and equipment related to new PSCs and new imaging equipment. General Expenses (- 18.2%) represented 0.3% of Net Revenue, a reduction of 10 bps. The reduction can be explained by lower labor costs. Gross Profit Gross Profit reached R$ 209.3 million, which represents growth of 8.3%. The gross margin in turn reached 30.6%, a reduction of 74 bps. In 9M18, Gross Profit increased by 9.2%. Gross margin reached 31.6%, a reduction of 70 bps. 9

Operating Expenses and Equity in Subsidiaries Operating Expenses totaled R$ 74.0 million in the quarter, which represents an increase of 13.3%. In relation to Net Revenue, this line represented 10.8%, an increase of 22 bps compared to the same period of 2017. In 9M18, they presented growth of 14.0% and advance of 23 bps in relation to Net Revenue. Operating Expenses breakdown and Equity in Subsidiaries R$ MM % Net Revenue R$ MM % Net Revenue % bps G&A 59.6 8.7% 54.8 8.9% 8.7% -18 bps Depreciation and Amortization 12.4 1.8% 10.6 1.7% 16.8% 9 bps Other Operating (Income) Expenses 0.6 0.1% 1.2 0.2% -48.8% -11 bps Provision (Reversal) for Contingency 1.7 0.2% (1.0) -0.2% -269.9% 41 bps Equity in Subsidiaries (0.3) 0.0% (0.4) -0.1% -21.6% 2 bps Operating Expenses and Subsidiaries' 74.0 10.8% 65.4 10.6% 13.3% 22 bps Operating Expenses breakdown and Equity in Subsidiaries R$ MM 3Q18 3Q17 Variation 9M 2018 9M 2017 Variação % Net Revenue R$ MM % Net Revenue % bps G&A 178.7 8.9% 159.5 8.9% 12.0% 3 bps Depreciation and Amortization 37.2 1.9% 31.7 1.8% 17.3% 9 bps Other Operating (Income) Expenses 5.2 0.3% 7.0 0.4% -25.8% -13 bps Provision (Reversal) for Contingency 3.8 0.2% (0.5) 0.0% -815.6% 22 bps Equity in Subsidiaries (0.8) 0.0% (1.1) -0.1% -26.2% 2 bps Operating Expenses and Subsidiaries' 224.1 11.2% 196.7 10.9% 14.0% 23 bps Below, the analysis of the main lines of operating expenses in 3Q18 compared to 3Q17: General and Administrative Expenses (+8.7%) accounted for 8.7% of Net Revenue, a reduction of 18 bps. They collaborated to improve, increase efficiency in the use of expenses related to consulting and maintenance of equipment. Depreciation and Amortization (+16.8%) amounted to 1.8% of Net Revenue, an increase of 9 bps. This increase is due to the increase in the amortization of IT systems. Other operational Income/Revenues (- 48.8%) accounted for 0.1% of Net Revenue, a reduction of 11 bps. The improvement is related to the sale of imaging equipment replaced in the period. Provision for Contingencies (- 269.9%) represented 0.2% of Net Revenue, growth of 41 bps, due to the increase in contingencies and provisions for civil risks compared to the previous period. Equity in Subsidiaries Grupo Papaiz, a dental diagnostics company in São Paulo, was acquired by the Fleury and Odontoprev at the end of 2012. The figures have been reported by equity equivalence method, considering the form of a Joint Venture in which Grupo Fleury holds a 51% stake of the business. Below is the performance in the 3Q18 and 9M18: Equity in Subsidiaries Papaiz R$ thousand % Net Revenue R$ thousand % Net Revenue Net Revenue 4,434.5 5,674.3-21.8% % bps EBITDA 1,179.0 26.6% 1,374.8 24.2% -14.2% 236 bps Net Income 577.9 13.0% 737.6 13.0% -21.6% 3 bps 3Q18 3Q17 Variation Net Income attributed to Grupo Fleury (51%) 294.7 376.2-21.6% 10

Equity in Subsidiaries Papaiz R$ thousand 9M 2018 % Net Revenue R$ thousand 9M 2017 % Net Revenue Net Revenue 15,803.7 15,495.5 2.0% Variation % bps EBITDA 3,627.3 23.0% 3,836.5 24.8% -5.5% -181 bps Net Income 1,602.2 10.1% 2,171.7 14.0% -26.2% -388 bps Net Income attributed to Grupo Fleury (51%) 817.1 1,107.6-26.2% EBITDA EBITDA reached R$ 181.5 million in the quarter, an increase of 11.1%. The EBITDA margin reached 26.6%, stable in relation to the previous period, despite impacts related to the expansion plan. The strong performance of Regional Brands, which contributed with 39% of participation in the gross revenue (470 bps more than in 3Q17), combined with efficiency gains and operating leverage, resulted in improvements of EBITDA margin neutralizing the effects of the new PSCs ramp up, as well as changes in the brands mix in the revenues. In 9M18, EBITDA increased by 11.9%, recording a margin of 27.2%. EBITDA (R$ MM) and margin (%) +11.1% 181.5 163.4 Gross Revenue (R$ MM) +11,9% 546,3 488,0 26.5% 26.6% 27,1% 27,2% 3Q17 3Q18 9M 2017 9M 2018 EBITDA R$ MM 3Q18 3Q17 Variation % Net Revenue R$ MM % Net Revenue % bps Net Income 90.3 13.2% 86.6 14.1% 4.4% -84 bps Financial Result 11.2 1.6% 11.2 1.8% 0.5% -17 bps Depreciation and Amortization 46.5 6.8% 35.9 5.8% 29.4% 97 bps Income Tax and Social Contribution 33.7 4.9% 30.1 4.9% 11.9% 4 bps Equity in Subsidiaries (0.3) 0.0% (0.4) -0.1% -21.6% 2 bps EBITDA 181.5 26.6% 163.4 26.5% 11.1% 3 bps EBITDA R$ MM 9M 2018 9M 2017 Variation % Net Revenue R$ MM % Net Revenue % bps Net Income 273.4 13.6% 256.0 14.2% 6.8% -61 bps Financial Result 36.8 1.8% 40.8 2.3% -9.8% -43 bps Depreciation and Amortization 135.2 6.7% 103.3 5.7% 30.9% 99 bps Income Tax and Social Contribution 101.7 5.1% 89.1 4.9% 14.1% 11 bps Equity in Subsidiaries (0.8) 0.0% (1.1) -0.1% -26.2% 2 bps EBITDA 546.3 27.2% 488.0 27.1% 11.9% 8 bps 11

EBIT (Operational Income) EBIT reached R$ 135.0 million in the quarter, a growth of 5.9%. The margin was 19.8%, a reduction of 95 bps. In 9M18, EBIT expanded 6.8%, reaching a margin of 20.5%, a reduction of 91 bps. EBIT (R$ MM) and margin (%) +5.9% 127.5 135.0 EBIT (R$ MM) and margin (%) +6.8% 411.1 384.7 20.7% 19.8% 21.4% 20.5% 3Q17 3Q18 9M 2017 9M 2018 Financial Result The financial result reached R$ -11.2 million, representing an increase of 0.5%. Financial expenses increased 19.7%, while financial revenues increased 37.6%. In 9M18, the financial result showed a reduction of 9.8%. Financial Result (R$ MM) 3Q18 3Q17 Variation 9M 2018 9M 2017 Variation Net financial income (11.2) (11.2) 0.5% (36.8) (40.8) -9.8% Financial income 16.4 11.9 37.6% 36.6 38.3-4.2% Earnings on financial investments 14.3 10.8 31.8% 32.9 34.3-4.0% Interest and inflation adjustment 2.1 1.1 95.2% 3.8 4.0-5.9% Financial expenses (27.6) (23.1) 19.7% (73.4) (79.0) -7.1% Interest on debentures and financing (23.0) (19.3) 19.1% (58.9) (64.7) -8.9% Interest and inflation adjustment (4.7) (3.8) 22.9% (14.5) (14.4) 1.1% Indebtedness In the quarter, the net debt/ltm EBITDA ratio reached 0.8x compared to 0.6x in the same period of 2017. Composition of Net Debt (R$ MM) 3Q17 2Q18 3Q18 Next 12 months Gross Debt (Debentures and Borrowings and Acquisitions ) 858.4 1,418.1 1,422.3 340.7 Cash, Cash Equivalents and Marketable Securities (482.7) (883.6) (889.8) Net Debt 375.7 534.5 532.6 Net Debt / EBITDA LTM 0.6x 0.8x 0.8x EBITDA LTM / Financial Result LTM 12.4x 14.6x 15.0x In the quarter, we amortized R$ 7.3 million referring to financing and payment of R$ 13.2 million of interest, related to debentures and financing. In 9M18, there was a release of R$ 500 million related to the fourth issue of debentures, the amortization of R$ 166.7 million related to the second issue of debentures and R$ 23.9 million related to financing. Interest paid in the period totaled R$ 50.3 million between debentures and financing. 12

Income Tax and Social Contribution In the quarter, income tax and social contribution on net income totaled R$ 33.7 million. The effective rate was 27.2% compared to 25.8% in 3Q17. In 9M18, income tax and social contribution on net income totaled R$ 101.7 million. The effective rate was 27.1% compared to 25.8% in the same period in 2017. Income Tax and Social Contribution (R$ MM) 3Q18 3Q17 Variation 9M 2018 9M 2017 Variation Earnings Before Tax (EBIT) 124.1 116.7 6.3% 375.1 345.1 8.7% Expected taxes (42.2) (39.7) 6.3% (127.5) (117.3) 8.7% Non-deductible expenses and incentives 1.7 0.8 105.9% 4.3 1.2 274.9% Effective taxes linearization 7.4 8.6-13.6% 21.3 26.7-20.4% Subsidiaries share of profits (0.7) 0.1-615.6% 0.3 0.4-26.3% Income tax and social contribution (33.7) (30.1) 11.9% (101.7) (89.1) 14.1% % EBIT 27.2% 25.8% 136 bps 27.1% 25.8% 129 bps Current (17.9) (4.1) 342.9% (78.9) (34.6) 127.9% Deferred (15.8) (26.1) -39.5% (22.8) (54.5) -58.2% Below is the expectation for the goodwill amortization for tax purposes, which reduces the cash tax. Expected Amortization of Goodwill Period Balance R$ MM 2018 2 2019 7 2020 7 Net Income Net Income reached R$ 90.3 million, an increase of 4.4%. The net margin was 13.2%, a decrease of 84 bps. In 9M18, Net Income reached R$ 273.4 million, an increase of 6.8%. Net margin reached 13.6%, a reduction of 61 bps. Net Profit (R$ MM) and margin (%) Net Profit (R$ MM) and margin (%) +4.4% 86.6 90.3 256.0 +6.8% 273.4 14.1% 13.2% 14.2% 13.6% 3Q17 3Q18 9M 2017 9M 2018 13

Cash Flow In the quarter, the Operating Cash Flow recorded R$ 173.5 million, which represents an increase of 1.7%. The conversion (Operating Cash/EBITDA) was 95.6%, compared to 104.4% in 3Q17. The average receivables collection reached 68 days versus 67 days in the 3Q17. Among the variations presented in working capital, we highlight the recoverable taxes, which due to a change in legislation, will be offset only in the next year of its incorporation, for which reason the account presented a negative variation. Investment activities recorded R$ -192.6 million compared to R$ -79.7 million in 3Q17. In the quarter, we recorded an increase in investments in marketable securities and fixed assets resulting from the Expansion Plan. Financing activities recorded R$ -72.8 million compared to R$ -45.7 million in 3Q17. In the quarter there were no new fund-raising and in 3Q17 there was a R$ 50.2 million fund-raising. In 9M18, the Operating Cash Flow registered R$ 489.3 million, an increase of 17.1%. The conversion (Operating Cash/EBITDA) was 89.6%. Investment activities reached R$ -655.0 million compared to R$ -247.1 million in the same period of the previous year. Financing activities recorded R$ -41.3 million versus R$ -171.5 million in 9M17. Cash Flow (R$ MM) 3Q18 3Q17 Variation 9M 2018 9M 2017 Variation Net Income 90.3 86.6 4.4% 273.4 256.0 6.8% Items not affecting cash: Financial revenues and expenses 22.7 13.3 70.7% 55.0 44.1 24.9% Depreciation and amortization 46.5 35.9 29.4% 135.2 103.3 30.9% Income tax and social contribution 33.7 30.1 11.9% 101.7 89.1 14.1% Provisions (Reversals) 16.5 17.1-3.5% 60.2 61.9-2.8% Others (0.1) (1.2) 94.5% 1.4 1.0 39.2% Net Income before non-cash effects 209.8 181.9 15.3% 627.0 555.4 12.9% Working capital: Accounts receivables (28.3) (29.5) 4.2% (68.4) (117.1) 41.6% Inventories 6.3 (4.7) 233.8% (0.4) 7.8-105.6% Taxes recoverable (11.1) 16.0-169.0% (20.5) 10.5-295.6% Suppliers (0.6) (6.7) 91.4% 13.5 (5.6) 341.3% Salaries / Charges 9.2 11.3-18.4% 14.0 (2.7) 618.5% Others Assets and Liabilities 7.4 4.8 54.6% (7.8) (0.5) -1378.7% Other Operating Cash Flow: Income tax and social contribution (19.3) (2.5) -680.0% (68.1) (29.9) -128.2% Cash Flow from Operating Activities 173.5 170.5 1.7% 489.3 417.8 17.1% Investment Activities: Acquisition of fixed and intangible assets (97.4) (83.5) -16.6% (183.4) (194.5) 5.7% Interest income and dividends received 2.4 7.6-68.7% 10.7 24.7-56.8% Marketable Securities (98.1) (3.8) -2452.6% (425.1) (76.8) -453.8% Acquisitions Payments 0.0 0.0 0.0% (57.3) (0.6) -9699.5% Others Investment Activities 0.5 0.0 0.0% 0.2 0.0 0.0% Cash Flow from Investing Activities (192.6) (79.7) -141.6% (655.0) (247.1) -165.1% Financing Activities Borrowings and Debentures Issue 0.0 50.2-100.0% 500.0 50.2 996.0% Others Financing Activities (18.3) (37.0) 50.6% (241.1) (100.1) -140.9% Dividends and/or interest on capital (57.6) (58.9) 2.3% (303.2) (130.1) -133.1% Capital increase 3.0 0.0 0.0% 3.0 8.4-64.3% Cash Flow from Financing Activities (72.8) (45.7) -59.3% (41.3) (171.5) 75.9% Cash Flow (91.9) 45.1-303.8% (207.0) (0.8) -24719.2% Cash Flow Adjusted by Marketable Securities 6.1 48.9-87.4% 218.1 75.9 187.3% Conversion (Operating Cash Flow / EBITDA) 95.6% 104.4% -877 bps 89.6% 85.6% 396 bps 14

Account Receivables In the comparison between quarters, there is a continuous improvement in the aging profile with the balances maturing, corresponding to 88.1% of the total, compared to 85.9% in 3Q17. The amount due over 121 days decreased from 5.8% in 3Q17 to 5.3% in 3Q18 and Accounts Receivable provisions over 121 days accounted for 76.6% of this amount (77.9% in 3Q17). Aging Account Receivable R$ MM 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 Trade Receivables 465.4 444.7 520.3 495.0 508.7 531.5 579.8 552.9 574.0 - Current 365.9 349.7 439.0 427.7 437.1 464.6 515.3 481.3 505.8 - Up to 120 days past due 37.7 36.7 31.6 34.1 42.1 35.9 34.6 44.1 37.7-121 to 360 days past due 38.2 31.3 26.6 22.1 20.7 24.8 26.0 22.1 21.4 - Over 361 days past due 23.6 27.0 23.1 11.2 8.8 6.1 4.0 5.4 9.1 Sales Deductions Provisions (40.9) (41.6) (40.6) (28.0) (23.0) (19.2) (21.4) (19.5) (23.4) Total 424.5 403.0 479.7 467.0 485.7 512.2 558.5 533.3 550.6 Current / Trade Receivables 78.6% 78.6% 84.4% 86.4% 85.9% 87.4% 88.9% 87.1% 88.1% Up to 120 days past due/ Trade Receivables 8.1% 8.2% 6.1% 6.9% 8.3% 6.8% 6.0% 8.0% 6.6% Over 121 days past due / Trade Receivables 13.3% 13.1% 9.5% 6.7% 5.8% 5.8% 5.2% 5.0% 5.3% Provisions / Over 121 days past due 66.1% 71.4% 81.7% 84.2% 77.9% 62.0% 71.3% 71.2% 76.6% 15

Expansion Plan In 3Q18, the Fleury Group inaugurated 6 a+ brand PSCs in São Paulo. In this way, from October 2016 to October 2018, 44 service PSCs were inaugurated. These inaugurations correspond to 60% of the minimum and 49% of the maximum bounds of the Company's Expansion Plan, which foresees the inauguration of 73 to 90 PSCs by 2021. PSCs inaugurated by brand Fleury Brand Complexity Patient Service Area (sqm) State Date 1 Fleury Santo André Medium 587 São Paulo feb/18 2 Fleury Carlos Weber Medium 681 São Paulo oct/17 3 Fleury Alameda Jaú Fast site 380 São Paulo set/17 4 Fleury Morumbi Large 1,988 São Paulo jul/17 5 Fleury Anália Franco Large 1,214 São Paulo jun/17 6 Fleury Heitor Penteado Fast site 183 São Paulo jun/17 7 Fleury São Caetano do Sul Fast site 411 São Paulo may/17 8 Fleury Cerro Corá Fast site 233 São Paulo apr/17 9 Fleury Ipiranga Fast site 206 São Paulo mar/17 10 Fleury Brasil Fast site 235 São Paulo jan/17 11 Fleury Moema Fast site 126 São Paulo dec/16 Regional South Complexity Patient Service Area (sqm) State Date 1 a+ João Bettega Small 128 Paraná dec/17 2 a+ Água Verde Small 171 Paraná may/17 3 Weinmann General Vitorino Small 113 Rio Grande do Sul may/17 4 a+ Ecoville Small 47 Paraná feb/17 5 a+ Champagnat Small 81 Paraná feb/17 6 a+ Centro Small 29 Paraná feb/17 7 a+ Batel Small 134 Paraná dec/16 8 a+ Nossa Saúde Small 79 Paraná oct/16 a+ São Paulo Complexity Patient Service Area (sqm) State Date 1 a+ São Bernardo do Campo Fast site 517 São Paulo sep/18 2 a+ Granja Viana Fast site 231 São Paulo aug/18 3 a+ Tatuapé Large 1,483 São Paulo aug/18 4 a+ Vila Andrade Fast site 234 São Paulo jul/18 5 a+ Brasil Fast site 348 São Paulo jul/18 6 a+ Alphaville Rio Negro Fast site 230 São Paulo jul/18 7 a+ Ipiranga Medium 359 São Paulo jun/18 8 a+ Funchal Fast site 239 São Paulo may/18 9 a+ Guarulhos Large 832 São Paulo apr/18 10 a+ Pedroso de Morais Medium 421 São Paulo dec/17 11 a+ Leôncio Magalhães Medium 544 São Paulo nov/17 12 a+ Queiroz Filho Medium 673 São Paulo oct/17 13 a+ Santo André Medium 437 São Paulo jul/17 14 a+ Augusto Tolle Fast site 392 São Paulo jul/17 15 a+ Itaim Bibi Fast site 207 São Paulo may/17 Regional RJ Complexity Patient Service Area (sqm) State Date 1 Felippe Mattoso Ipanema Fast site 239 Rio de Janeiro dec/17 2 Labs a+ Catete Fast site 145 Rio de Janeiro dec/17 3 Labs a+ Shopping Santa Cruz Fast site 131 Rio de Janeiro dec/17 4 Labs a+ Mariz e Barros Fast site 134 Rio de Janeiro dec/17 5 Labs a+ Uruguai Fast site 129 Rio de Janeiro nov/17 6 Labs a+ Santa Rosa Fast site 148 Rio de Janeiro oct/17 7 Labs a+ Campo Grande Fast site 281 Rio de Janeiro set/17 Regional Brasília Complexity Patient Service Area (sqm) State Date 1 a+ Asa Sul Fast site 58 Brasília aug/17 2 a+ Sudoeste Fast site 119 Brasília aug/17 Regional Pernambuco Complexity Patient Service Area (sqm) State Date 1 a+ Casa Forte Small 151 Pernambuco may/18 Total 44 PSCs 15,707 sqm Additionally, we listed below the 5 PSCs from the acquisitions, being 4 PSCs of the Institute of Radiology of Natal (IRN) and 1 of Serdil. PSC Complexity Patient Service Area (sqm) State Date 1 IRN - Instituto de Radiologia Matriz NA 1,697 Rio Grande do Norte NA 2 IRN - Instituto de Radiologia Parnamirim NA 477 Rio Grande do Norte NA 3 IRN - Instituto de Radiologia Zona Sul NA 1,317 Rio Grande do Norte NA 4 IRN - Harmony Center NA 98 Rio Grande do Norte NA 5 Serdil 0 0 NA 1,213 Rio Grande do Sul NA Total 5 PSCs by acquisition 4,801 16

Investiments Investments (additions to fixed and intangible assets) totaled R$ 96.9 million in the quarter, of which 61.0% were concentrated in the Expansion Plan and improvements in PSCs. Compared with 3T17, there was an increase of 37.9%. In 9M18, investments reached R$ 182.4 million, with 56.2% dedicated to the Expansion Plan and improvements in PSCs. The Other group consists of strategic projects, infrastructure, IT and equipment renovation. CAPEX (R$ MM) +37.9% 96.9 70.3 61.0% 65.7% CAPEX (R$ MM) -6.2% 194.5 182.4 65.7% 56.2% 34.3% 39.0% 34.3% 43.8% 3Q17 3Q18 Expansion and improvement in PSCs and Central Labs Others 9M 2017 9M 2018 Expansion and improvement in PSCs and Central Labs Others Stock Market Performance Fleury shares (B3: FLRY3) at the end of 3Q18 were quoted at R$ 22.14. The Average Daily Trading Volume (ADTV) for the period was R$ 38.5 million, an amount 29.4% lower than that registered in the same period of 2017. Average Daily Trading Volume (ADTV) R$MM 0.697% IN ADTV 0.610% 0.541% 0.555% 0.470% 0.375% 0.374% 0.246% 0.086% 0.057% 5.5 3.0 3.0 25.4 28.6 54.4 57.5 53.0 50.4 38.5 2014 2015 2016 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 * Índice de Negociabilidade Investor Relations Phone: + 55 11 5014-7413 E-mail: ri@grupofleury.com.br Website: www.fleury.com.br/ri Address: Avenida General Valdomiro de Lima, 508-04344-903 - São Paulo, SP Brasil 17

Performance Indicators Operational Indicators Description Unit 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 Income Statment Gross Revenue Gross Revenue R$ MM 572.4 642.1 646.5 667.7 630.2 706.3 728.1 738.5 Net Revenue COGS SG&A Gross Revenue - Tax (ISS and PIS/COFINS) - Cancellations Personnel and Medical Services + Materials and Outsourcing + General Services, Rent and Utilities + General Expenses + Depreciation and Amortization Does not include Other Operating Expenses / Revenues neither Contingency Provisions R$ MM 523.2 587.8 597.6 615.6 582.0 653.3 673.4 683.0 R$ MM -391.4-385.2-410.9-422.4-428.5-439.9-460.1-473.7 R$ MM -69.1-58.5-67.2-65.5-65.3-69.3-74.7-72.0 EBIT Earnings Before Interest and Taxes R$ MM 63.1 139.7 117.5 127.5 91.2 141.7 134.3 135.0 EBITDA Earnings Before Interest, Taxes, Depreciation and Amortization R$ MM 100.7 173.2 151.4 163.4 130.7 185.9 178.8 181.5 Net Finance Income Interest Revenue - Interest Expenses R$ MM -6.6-16.9-12.7-11.2-8.3-10.7-14.8-11.2 Net Income Net Income R$ MM 74.9 81.6 87.9 86.6 64.6 96.4 86.6 90.3 Net Cash Income Net Income - Deferred income tax R$ MM 75.1 105.6 92.2 112.7 82.2 104.3 85.7 106.1 Result Indicators Cancellation Index Cancellations / Gross Revenue % -2.4% -2.3% -1.4% -1.7% -1.5% -1.4% -1.4% -1.5% Gross Margin Gross Profit / Net Revenue % 25.2% 34.5% 31.3% 31.4% 26.4% 32.7% 31.7% 30.6% EBIT Margin Earnings Before Interest and Tax / Net Revenue % 12.1% 23.8% 19.7% 20.7% 15.7% 21.7% 19.9% 19.8% EBITDA Margin Earnings Before Interest, Tax, Depreciation and Amortization / Net Revenue % 19.3% 29.5% 25.3% 26.5% 22.4% 28.5% 26.6% 26.6% Effective Tax Rate Current Tax / Earnings Before Tax % 32.3% -33.8% -16.4% -25.8% -21.8% -26.6% -27.6% -27.2% Net Margin Net Profit / Net Revenue % 14.3% 13.9% 14.7% 14.1% 11.1% 14.8% 12.9% 13.2% Net Cash Income Margin (Net Income - Deferred income tax) / Net Revenue % 14.4% 18.0% 15.4% 18.3% 14.1% 16.0% 12.7% 15.5% Financial Debt Cash & Equivalents Cash, Equivalents and Marketable Securities R$ MM 406.8 337.2 433.8 482.7 671.8 470.5 883.6 889.8 Gross Debt Short and Long Term Debts (Borrowings and Debentures) R$ MM 840.0 825.4 837.5 858.4 1,069.6 919.7 1,418.1 1,422.3 Net Debt Gross Debt - Cash and Cash equivalents R$ MM 433.2 488.2 403.7 375.7 397.7 449.2 534.5 532.6 Net Debt / EBITDA LTM (Gross Debt - Cash and Cash equivalents) / EBITDA LTM Multiple 0.9x 0.9x 0.7x 0.6x 0.6x 0.7x 0.8x 0.8x Profitability and Return NOPAT LTM (tax= 34%) / Capital Employed ROIC without Goodwill (LTM) (Shareholders Equity + Net Debt - Goodwill) % 32.5% 35.6% 39.8% 43.6% 43.8% 43.6% 41.9% 41.3% 18

Assets 09/30/2018 12/31/17 Liabilities and equity 09/30/2018 12/31/17 FLEURY S.A. CONSOLIDATED Balance Sheet as of September and December 31, 2017 (In R$ thousands) Current Current Cash and cash equivalents 130,335 337,544 Financing 33,006 30,948 Marketable securities 759,434 334,286 Debentures 293,372 284,693 Derivative financial instruments 225 17 Financial lease 610 606 Accounts receivable 550,611 512,241 Derivative financial instruments - - Inventories 21,983 21,545 Trade accounts payable 162,032 148,485 Taxes recoverable 30,886 27,028 Payroll and related taxes payable 137,758 100,354 IRPJ e CSLL recoverble 38,851 22,258 Taxes and contributions payable 24,875 30,575 Credits receivable 4,752 3,854 IRPJ e CSLL payable 10,516 59 Related Parties 98 - Accounts payable - company acquisition 14,363 1,855 Other assets 22,430 8,264 Dividends payable 22 41,420 Total current 1,559,605 1,267,037 Other accounts payable 850 151 Total current 677,404 639,146 Credits receivable 3,528 12,694 Non-current Dividends receivable 26 - Financing 83,614 105,949 Other assets 4,509 9,555 Debentures 966,667 633,334 Judicial deposits 48,365 47,521 Financial lease 6,354 6,769 Deferred income tax and social contribution, ne 386,196 362,777 Provision for tax, labor and civil risks 29,509 30,480 Taxes and contributions payable 30,242 29,549 Accounts payable - company acquisition 31,301 12,800 Total non-current 1,533,883 1,181,658 Share capital 1,416,603 1,413,608 Capital reserve - options granted recognized 24,077 17,923 Revaluation reserve - 78 Investments 12,397 11,296 Legal reserve 70,681 70,681 Property and equipment 705,266 641,920 Retained earnings - 204,238 Intangible assets 1,604,788 1,537,309 Additional dividends proposed 215,836 - Total non-current 2,378,879 2,260,295 Total equity 1,727,197 1,706,528 Total assets 3,938,484 3,527,332 Total liabilities and equity 3,938,484 3,527,332 Non-current Equity 19

CONSOLIDATED Income Statement as of September and 2017 (R$ thousands) 3Q18 3Q17 Revenue from services rendered 683,036 615,586 Cost of services rendered (473,700) (422,373) - - Gross Profit 209,336 193,213 Operating income (expenses) General and administrative (72,020) (65,478) Other operating income (expenses), net (636) (1,244) Provision for tax, labor and civil risks (1,685) 992 Equity in the earnings (losses) of subsidiaries 295 376 - - Operating profit before financial result 135,290 127,859 Financial income 16,424 11,935 Financial expenses (27,641) (23,091) - - Financial result (11,217) (11,156) Earnings before income tax and social contribution 124,073 116,703 Income tax and social contribution: Current (17,946) (4,052) Deferred (15,786) (26,090) - - Profit for the period 90,341 86,561 Earnings per share attributable to owners of the Company Basic earnings per share (weighted average) 0.29 0.28 Diluted earnings per share (weighted average) 0.28 0.27 20

Balances on December 31, 2015 Capital increase Realization of revaluation reserve Stock option plan Profit for the period (R$1.46 per share) Dividends from previous period Profit allocation: Legal Reserve Interest on own capital Share Capital Share Capital Capital Reserve Investment Reserve Share issue expenses Options granted recognized Revaluation reserve Legal Reserve Profit Reserve Investment Reserve Profit for the period 1,402,531 (22,784) 5,709 242 43,213-215,762-10,766 1,655,439 Additional dividends proposed 20,706 - - - - - - - - 20,706 - - - (165) - - 165 - - - - - 3,703 - - - 926 - - 4,629 - - - - - - - 228,749-228,749 - - - - - - (216,853) - (10,766) (227,619) - - - - - - - - - - - - - - 11,437 - - (11,437) - - - - - - - - - (110,425) - (110,425) Equity FLEURY S.A. CONSOLIDATED Statements of Changes in Equity as of September and December 31, 2017 and 2016 (R$ thousands) 'Dividends - - - - - - - (106,887) 71,133 (35,754) Balances on December 31, 2016 Realization of revaluation reserve Capital increase Stock option plan Profit for the period (R$1.02 per share) Profit allocation Legal Reserve Interest on own capital 'Dividends Balances on December 31, 2017 Capital increase Stock option plan Profit for the period (R$0,87 per share) 'Dividends Interest on own capital Revaluation reserve Balances on December 31, 2017 - - - - - - - - - - 1,423,237 (22,784) 9,412 77 54,650 - - - 71,133 1,535,725 - - - 1 - - - - - 1 13,155 - - - - - - - - 13,155 - - 8,511 - - - - - - 8,511 - - - - - - - 320,618-320,618 - - - - - - - - - - - - - - 16,031 - - (16,031) - - - - - - - - - (100,349) (71,133) (171,482) - - - - - 204,238 - (204,238) - - 1,436,392 (22,784) 17,923 78 70,681 204,238 - - - 1,706,528 2,995 6,154 (78) 1,439,387 (22,784) 24,077-70,681 - - 215,836-1,727,197 (204,238) 273,402 (57,566) 21

CONSOLIDATED Statements of Cash Flow as of September and 2017 (R$ thousands) 3Q18 3Q17 Profit for the period 90,341 86,561 Items not affecting cash: Income tax and social contribution 33,731 30,142 Financial and expenses income 22,726 13,311 Depreciation and amortization 46,513 35,935 Equity in the earnings (losses) of subsidiaries (295) (377) Stock option plan 1,967 2,177 Constitution (reversal) of provision for tax, labor and civil risks (2,037) (992) Estimated losses with allowance for doubtful accounts 11,016 10,806 Profit sharing 5,598 5,153 Other 230 (832) Cash flows from operating activities before changes in assets and liabilities 209,790 181,884 - (Increase) decrease in accounts receivable (28,288) (29,531) (Increase) decrease in inventories 6,306 (4,714) (Increase) decrease in taxes recoverable (11,052) 16,010 (Increase) decrease in judicial deposits (103) (1,099) (Increase) decrease in other assets 2,898 6,157 Increase (decrease) in trade accounts payable (579) (6,748) Increase (decrease) in payroll and related charges 9,225 11,298 Increase (decrease) in tax liabilities 2,278 849 Increase (decrease) in taxes paid in installments (978) (1,203) (Increase) decrease in other liabilities 3,323 120 Total variation in assets and liabilities (16,970) (8,861) Income tax and social contribution paid (19,314) (2,477) Net cash from operating activities 173,506 170,546 Acquisition of property and equipment and intangible assets (97,380) (83,528) Sale of fixed assets 660 - Marketable securities and interest earned (98,086) (4,376) Redemption of marketable securities - 534 Payments - - Payments excepted cash - - Related parties increase 1,192 - Acquisition of (1,387) Interest earned from financial investments 2,389 7,630 Net cash used in investing activities (192,612) (79,740) Borrowings and debentures - 50,203 Settlement (principal) of financing and debentures (7,329) (5,760) Interest paid in financing and debentures (13,209) (29,795) Financial expenses paid (780) (1,285) Derivative financial instruments (148) (156) Capital integralization 2,995 - Dividends and / or interest on shareholders' equity (57,566) (130,071) Dividends - - Related Parties - 71,159 Other (550) Risk Withdrawn Operation 3,756 Net cash used in financing activities (72,831) (45,705) (Decrease) increase in cash and cash equivalents (91,937) 45,101 Cash and cash equivalents At the beginning of the period 222,272 267,899 At the end of the period 130,335 313,000 Variation in cash and cash equivalents (91,937) 45,101 22

CONSOLIDATED Statements of Value Added as of September and 2017 (R$ thousands) 09/30/18 09/30/17 Revenues 2,149,369 1,922,151 Goods and products sold and services rendered 2,172,230 1,955,886 Estimated losses with allowance for doubtful accounts (30,638) (34,433) Other revenue 7,777 698 Inputs purchased from third parties (770,219) (697,031) Cost of goods and products sold and services rendered (712,521) (646,766) Materials, electricity, outsourced services and others (56,749) (49,360) Loss/recovery of asset values (949) (905) Gross value added 1,379,150 1,225,120 Depreciation and amortization (135,227) (103,275) Net value added 1,243,923 1,121,845 Value added received through transfer 39,193 41,181 Equity in the earnings (losses) of subsidiaries 817 1,107 Financial income 38,376 40,074 - - Total value added 1,283,116 1,163,026 - - Distribution of value added (1,283,116) (1,163,026) Personnel and charges (470,918) (424,693) Direct remuneration (323,681) (288,557) Benefits (119,424) (112,251) Charges (27,813) (23,885) Taxes, fees and contributions (329,152) (294,615) Federal (263,702) (238,523) Municipalities (65,450) (56,092) State - - Interest, rental and other operating expenses (209,644) (187,736) Interest (118,360) (98,943) Rental (73,421) (79,028) Other operating expenses (17,863) (9,765) Dividends and/or Interest on Equity (57,566) (58,941) Legal Reserve - - Retained earnings (215,836) (197,041) 23

Table of contents Parent company and consolidated interim financial information Statement of financial position... 1 Statement of income... 2 Statement of comprehensive income... 3 Statement of changes in equity... 4 Statement of cash flows... 5 Statement of value added... 6 Notes to the parent company and consolidated interim financial information 1. General information... 8 2. Presentation of the financial statements and summary of the main accounting practices adopted... 8 3. Risk management... 17 4. Cash and cash equivalents... 23 5. Marketable securities... 24 6. Derivative financial instruments Parent Company and... 24 7. Trade receivables... 25 8. Inventories... 26 9. Taxes recoverable... 26 10. Judicial deposits... 27 11. Receivables... 27 12. Investments... 27 13. Property and equipment... 29 14. Intangible assets... 31 15. Financing... 33 16. Debentures... 34 17. Finance lease... 36 18. Trade payables... 37 19. Payroll and related charges... 37 20. Taxes and contributions payable... 37 21. Accounts Payable Company acquisition... 38 22. Income tax and social contribution Deferred... 39 23. Provision for tax, labor and civil risks... 40 24. Operating lease... 43 25. Related parties... 43 26. Equity... 45 27. Employee benefit... 46 28. Revenue from services rendered... 49 29. Cost of services... 49 30. General and administrative expenses... 50 31. Other operating income (expenses), net... 51 32. Financial result... 51 33. Earnings per share... 53 34. Segment reporting... 53 35. Insurance... 54 36. Events after the reporting period... 54 Page 7 of 53

1. General information 1.1 The Company Fleury S.A. ( Fleury, Parent Company or Company and, jointly with its subsidiaries, Grupo Fleury or Group ) is a publicly held company listed in the Novo Mercado special segment of B3 S.A. Brasil, Bolsa e Balcão, under ticker FLRY3. The Company is headquartered in the city of São Paulo and operates in the states of São Paulo, Rio de Janeiro, Rio Grande do Sul, Paraná, Bahia, Rio Grande do Norte, Pernambuco and the Federal District. The Group s purpose is to render medical services in the diagnostic, treatment and clinical analysis areas. On March 1, 2018, Fleury S.A. acquired 100% of the share capital of the companies comprising Instituto de Radiologia de Natal (IRN), a company that provides diagnostic imaging services and has four units in the Rio Grande do Norte State. On September, the Company had 178 patient service centers and 23 operations in hospitals in Brazil s main economic centers, distributed across eight brands: Fleury, Weinmann, Clínica Felippe Mattoso, a+, Labs a+, Diagnoson a+, Serdil and Instituto de Radiologia de Natal (IRN). 2. Presentation of the financial statements and summary of the main accounting practices adopted 2.1. Basis of presentation a) Parent company and consolidated interim financial information Grupo Fleury s interim financial information was approved by the Board of Directors at a meeting held on October 24, 2018. Fleury s parent company and consolidated interim financial information for the periods ended September and 2017 has been prepared in accordance with the Brazilian Accounting Pronouncement CPC 21 (R1) (Interim Financial Reporting) and the international standard IAS 34 Interim Financial Reporting, issued by the International Accounting Standards Board IASB, and presented in conformity with the standards issued by the Brazilian Securities and Exchange Commission CVM, applicable to the preparation of the Interim Financial Information Form ITR. The accounting practices and policies (which include measurement, recognition, and asset and liability assessment principles), in addition to the main accounting judgments and sources of uncertainties on the estimates adopted when preparing this interim financial information are consistent with those adopted and disclosed in Note 2 of the annual financial statements referring to the year ended December 31, 2017, and, therefore, must be analyzed as a whole, except for policies related to the financial assets and liabilities and revenue recognition originally disclosed in items Page 8 of 53

2.3, 2.9 and 2.13, respectively, which changed due to the first-time adoption of CPC 47 and CPC 48, described in items 2.2 and 2.3. The parent company and consolidated financial information is presented in thousands of Brazilian reais (R$), which is Grupo Fleury s functional and reporting currency. b) Consolidation The Company consolidates all the entities it controls, i.e. when it is exposed or has rights to variable returns and is able to manage important activities of the investee. Intercompany transactions, balances and unrealized gains and losses in intragroup transactions are eliminated. The subsidiaries accounting practices are consistent with those adopted by the Company. The consolidated interim financial information includes the balances of Fleury S.A., subsidiaries and special purpose entities represented by the exclusive investment funds, as shown below: Fleury S.A. s interest held in the share capital % Company and subsidiaries: Type 9/30/2018 12/31/2017 Description Fleury Centro de Procedimentos Médicos Avançados ( Fleury CPMA ) Direct 100% 100% Diagnostic imaging activities in certain hospitals Serdil Serviço Especializado em Radiodiagnóstico Ltda. Instituto de Radiologia de Natal Ltda. ( IRN ) Indirect 100% 100% Diagnostic imaging Indirect 100% - Diagnostic imaging Cardionuclear Natal Ltda. Indirect 100% - Diagnostic imaging Radiodonto Natal Ltda. Indirect 100% - Diagnostic imaging Exclusive investment funds: Bradesco Fundo de Investimento em cotas de FI Renda Fixa Crédito Privado Exclusivo Beta Santander FI Exclusivo Alpha Renda Fixa Crédito Privado Longo Prazo Direct 100% 100% Exclusive investment fund Direct 100% 100% Exclusive investment fund Page 9 of 53

c) Joint venture Interest accounted for by the equity accounting method, as follows: Fleury CPMA s interest held in the share capital % Company Type 9/30/2018 12/31/2017 Description Papaiz Associados Diagnóstico por Imagem S/A Ltda. Indirect 51% 51% Dental radiology operation d) Business combination In order to complement its existing offering of clinical analysis in the North region and reinforce the positioning of its diagnostic medicine portfolio, on March 1, 2018 (closing date), the Company acquired 100% of the share capital of the companies jointly referred to as Instituto de Radiologia de Natal (IRN), a traditional medical diagnostic company specialized in imaging services that has been operating for nearly 50 years in the cities of Natal and Paranamirim, in the Rio Grande do Norte State. IRN was acquired for R$90.5 million, which corresponds to 5.9x EBITDA of the last 12 months ended in October 2017, of R$15.3 million. A portion of the amount was paid in cash and the remaining R$32.0 million was retained, R$1.0 million of which for price adjustment purposes after final analysis of working capital and net debt, and R$31.0 million will be held in an escrow account and released as follows: i) R$11.0 million upon entry of the real estate registrations; ii) R$1.6 million to cover litigations whose release terms have not been agreed upon; and iii) R$18.4 million have not been allocated (other losses), 1/3 of which will be released on the third anniversary, 1/3 on the fourth anniversary and 1/3 on the fifth anniversary of the closing date. Gross acquisition price 90,500 (-) Payment in cash (58,500) Retained balance 32,000 Current 12,000 Noncurrent 20,000 Identifiable net assets acquired and goodwill Th The difference between the consideration transferred in exchange for control of IRN and its net assets at fair value resulted in the recognition of goodwill and certain intangible assets. The allocation of the consideration/amount paid was based on a preliminary assessment of the fair value of the net assets acquired from IRN on March 1, 2018. Page 10 of 53

The fair value of the identifiable net assets acquired and the assumed liabilities in the business combination were estimated based on the projected discounted cash flow method and replacement cost. The fair value was estimated using the discounted cash flow method based on a discount rate of 13.3% p.a. The non-identifiable net assets in this business combination were recorded under goodwill. The assets and liabilities acquired and recognized on the acquisition date are as follows: Assets 3/01/2018 Cash and cash equivalents 18,671 Trade receivables 2,348 Inventories 577 Other assets 2,108 Property and equipment and intangible assets 10,210 Total assets 33,914 Liabilities Trade payables 1,450 Tax obligations 340 Labor obligations 1,162 Profit and dividends payable (*) 16,000 Other liabilities 1,109 Total liabilities 20,061 Net assets acquired 13,853 The allocation of the consideration transferred is as follows: Gross acquisition price 90,500 Net debt 2,367 Acquisition price, net 92,867 Working capital (5,121) Adjusted acquisition price (consideration transferred) 87,746 Equity (13,853) Goodwill Property and equipment (3,132) Goodwill Intangible assets (trademark) indefinite useful life (4,952) Net equity fair value (21,937) Goodwill (*) 65,809 (*)The change in goodwill disclosed in the previous quarter refers to the conclusion of the purchase price allocation (PPA) report, which included net debt, working capital and goodwill. See reconciliation below: Page 11 of 53

6/30/2018 Change 9/30/2018 Gross acquisition price 90,500-90,500 Net debt - 2,367 2,367 Acquisition price, net 90,500 2,367 92,867 Working capital - (5,121) (5,121) Adjusted acquisition price (consideration transferred) 90,500 (2,754) 87,746 Equity (13,853) - (13,853) Goodwill Property and equipment - (3,132) (3,132) Goodwill Intangible assets (trademark) - (4,952) (4,952) Net equity fair value (13,853) (8,084) (21,937) Goodwill 76,647 (10,838) 65,809 e) Changes in the main accounting policies The Group adopted CPC 47/IFRS 15 and CPC 48/IFRS 9 using the cumulative effect method, with effect of initial adoption on January 1, 2018. Consequently, the information presented for 2017 was not restated; it was presented as previously reported in accordance with CPC 30/IAS 18, CPC 17/IAS 11 and related interpretations. Regarding CPC 47, on September, there were no impacts on the statement of financial position, statement of income, statement of comprehensive income and statement of cash flows, given that the Company s operations already met the criteria required by the new standard, except for the disclosure of qualitative information, which is being reported in this quarterly information to comply with the new standard. Regarding CPC 48/IFRS 9, there was an impact on the presentation of estimated default losses, previously reported as a deduction of gross revenue, and which, as of January 1, 2018, were recorded under Other operating expenses. On September, said amount totaled R$2,104. 2.2 New accounting policy for financial instruments (effective as of January 1, 2018) a) Financial assets Classification The Company classifies its financial assets in the following categories: i) amortized cost and ii) fair value through profit or loss. These classifications are based on the business model adopted for asset management and on the characteristics of contractual cash flows. Page 12 of 53

- Amortized cost Financial assets held to generate contractual cash flows are recognized at amortized cost. These flows are received on specific dates and exclusively comprise payment of principal and interest. Some of the assets classified in this category are Trade receivables and Other receivables. - Fair value through profit or loss Assets recognized at fair value through profit or loss comprise: i) those that do not fit the business models that allow the classification at amortized cost or fair value through other comprehensive income; ii) equity instruments at fair value through profit or loss; iii) financial assets managed to obtain cash flow from the sale of assets. The following assets classified in this category are Cash and cash equivalents and Government bonds and Secured short-term investments classified as Securities and Derivative financial instruments. Initial measurement Upon initial recognition, the entity s financial assets and liabilities are measured at fair value, taking into consideration the transaction costs attributable to the acquisition or issue of a financial asset or a financial liability. Trade receivables are initially measured at transaction cost. Subsequent measurement Based on asset classification, subsequent measurement is as follows: - Amortized cost Assets classified under this business model are accounted for using the effective interest rate method less expected credit losses. In addition, the principal amount paid is included in the calculation of amortized cost. - Fair value through profit or loss Assets classified under this business model are accounted for based on the recognition of gains or losses recorded in profit/loss for the period. For the current period, no other financial assets have been classified at fair value through profit or loss except for those already mentioned in Note 2.2 of the financial statements for the year ended December 31, 2017. Impairment The Company records a provision for expected credit losses for assets classified at amortized cost. The impairment test is carried out prospectively, based on historical data and models created for such purpose. In addition, the financial assets credit risk changes are tested for impairment every month in order to reflect the risk of default to which the Company is subject and the amount to be used as a base for the recognition of losses, i.e., if the credit risk does not significantly increase, a credit loss should be recognized on the outstanding balance for the next 12 months and, if the Company identifies a significant increase in credit risk, it records loss based on the total outstanding amount for the entire life of the financial instrument. The following financial assets held by the Company are subject to the creation of a provision for impairment: Trade receivables (see Note 7); Receivables (see Note 11). Page 13 of 53

b) Financial liabilities Classification The Company s financial liabilities are classified at: Amortized cost, represented by Trade payables, Borrowings and financing, and Finance lease; Fair value through profit or loss, represented by Derivative financial instruments. Initial recognition Financial liabilities are initially recognized at fair value plus transaction costs (in the case of borrowings, financing, and accounts payable). The Company s financial liabilities comprise accounts payable, borrowings, financing, financial guarantee agreements and derivative financial instruments. Subsequent measurement Based on asset classification, subsequent measurement is as follows: - Amortized cost Liabilities classified at amortized cost are accounted for using the effective interest rate method, in which gains and losses are recorded in profit or loss when liabilities are written-off and upon recognition of amortization. - Fair value through profit or loss Liabilities classified at fair value through profit or loss are accounted for through the recognition of their gains or losses in profit/loss for the period. The summary of the new classification is as follows: Financial asset/liability Previous classification IFRS 9 Cash and cash equivalents Fair value through profit Fair value through profit or loss or loss Operating trade receivables Borrowings and receivables Amortized cost Marketable securities Government bonds Fair value through profit or loss Fair value through profit or loss Marketable securities - Secured shortterm investments or loss Fair value through profit Assets held to maturity Receivables Borrowings and receivables Amortized cost Judicial deposits Borrowings and receivables Amortized cost Trade payables Other financial liabilities Amortized cost Financial instruments Fair value through profit Fair value through profit or loss or loss Borrowings and financing Borrowings and receivables Amortized cost Operating lease Other financial liabilities Amortized cost Page 14 of 53

2.3 New accounting policy for revenue recognition (effective as of January 1, 2018) 2.3.1 Services rendered Revenue is recognized when control and all other rights and benefits arising from the provision of services flow to the client, i.e. when test results are issued, approximately at the same time as the test is performed. The allocation of compensation for services provided mainly refers to clinical analysis that have a single defined performance obligation (test/analysis) and whose transaction price is agreed upon between the Company and its respective clients. In this case, there is no variable consideration, return or refund obligations, as well as no significant financing component or remaining performance obligations. The agreements entered into between the Company and its respective clients have a commercial substance since they are approved by the parties, and the rights of each party, as well as payment conditions, are identified. The performance obligation in these agreements refers to the execution of clinical analysis tests, which begins with the collection of the material and ends with the issue of diagnostic test results that are available to users on the Company s website or in the patient service centers. Diagnostic medicine and integrated medical services do not differ regarding the performance obligations to be complied with. Revenue from services rendered is already net of any estimated rebates, discounts and disallowances. a) Main service lines Diagnostic Medicine Laboratory and image exams for clients assisted in Grupo Fleury s own units. Integrated Medicine It caters to hospitals that integrate diagnostic services with specialized clinical staff and clinical analysis exams, providing high added value diagnostic information to the physicians of said institutions. It also comprises check-up and reference laboratory (LARE) services. Dental Dental imaging exams conducted by the joint venture Papaiz and the indirect subsidiary Radiodonto Natal. b) Expected remuneration Services rendered to clients are remunerated as follows (amounts contractually agreed upon): i) clinical analysis services, based on the volume of analyses; and ii) defined clinical analysis packages, based on pre-defined procedure packages (check-up). Page 15 of 53

c) Estimated losses with disallowances Estimated losses with disallowances are recorded based on historical analysis and commercial trends. In 3Q18, the estimate adopted by the Company was 1.4% of revenue (1.7% in 3Q17), billed or not. This estimate is reviewed by the Company at the end of each reporting period. d) Estimated losses with doubtful accounts Estimated losses with doubtful accounts are recorded based on the historical negotiation average, confession of debt with late installments and negotiation with a low probability of success, as mentioned in item 2.2 and Note 7. There was no impact related to accounting adjustments arising from the adoption of CPC 48, given that the previous practice adopted by the Company already reflected the items required by the new standard. 2.4. New standards, amendments and interpretations of standards issued by IASB and the CPC The following standard was issued by IASB but is not yet effective for 2018. Although encouraged by IASB, early adoption is not allowed by the Brazilian Accounting Pronouncements Committee (CPC). IFRS 16 (CPC 06- R2) Leases This standard determines that lessees recognize the right to use the leased asset and the liabilities arising from future payments of lease agreements, including operating leases with exemptions for short-term or low-value agreements. This pronouncement should be applied as of January 1, 2019. The Company hired an independent company to help it identify the agreements and is reviewing the internal controls and the systemic environment involved in this amendment. The main impacts of the adoption of this standard are provided for on the recognition of operating lease agreements (see Note 24). 2.5. Expanded disclosure On September, the Company expanded the presentation of the statement of value added, mainly in aspects related to value added distribution, in order to report more transparent figures. Below are the impacts of the reclassifications in the immediately preceding period: Page 16 of 53

Parent Company 9/30/2017 9/30/2017 9/30/2017 9/30/2017 (previously (previously Reclassification (reclassified) Reclassification (reclassified) disclosed) disclosed) Revenue 1,911,805 (438) 1,911,367 1,922,588 (437) 1,922,151 Revenue from services rendered 1,945,578 (438) 1,945,140 1,956,323 (437) 1,955,886 Estimated losses with disallowances and doubtful accounts (34,471) - (34,471) (34,433) - (34,433) Other revenue 698-698 698-698 Input acquired from third parties (685,506) (3,143) (688,649) (693,854) (3,177) (697,031) Cost of services (515,739) (122,715) (638,454) (524,086) (122,680) (646,766) Materials, electricity, outsourced services and others (168,862) 119,572 (49,290) (168,863) 119,503 (49,360) Loss/recovery of asset values (905) - (905) (905) - (905) Gross value added 1,226,299 (3,581) 1,222,718 1,228,734 (3,614) 1,225,120 Depreciation and amortization (102,815) (2) (102,817) (103,273) (2) (103,275) Net value added 1,123,484 (3,582) 1,119,901 1,125,461 (3,616) 1,121,845 Value added received through transfer 39,721 1,803 41,525 39,361 1,820 41,181 Equity in the earnings (losses) of subsidiaries 2,417-2,417 1,108 (1) 1,107 Financial income 37,304 1,804 39,108 38,253 1,821 40,074 Total value added to distribute 1,163,205 (1,779) 1,161,427 1,164,822 (1,796) 1,163,026 Distribution of value added (1,163,205) 1,779 (1,161,426) (1,164,822) 1,796 (1,163,026) Personnel and charges (498,193) 73,500 (424,693) (498,193) 73,500 (424,693) Direct compensation (288,359) (198) (288,557) (288,359) (198) (288,557) Benefits (112,250) (1) (112,251) (112,250) (1) (112,251) Charges (97,584) 73,699 (23,885) (97,584) 73,699 (23,885) Taxes, fees and contribution (215,908) (77,694) (293,602) (216,905) (77,710) (294,615) Federal (159,365) (78,360) (237,725) (160,147) (78,376) (238,523) Municipal (55,877) - (55,877) (56,092) - (56,092) State (666) 666 - (666) 666 - Interest, rental and other operating expenses (193,122) 5,973 (187,149) (193,742) 6,006 (187,736) Rental (61,127) (37,816) (98,943) (61,128) (37,815) (98,943) Interest (93,032) 14,586 (78,446) (93,031) 14,003 (79,028) Other operating expenses (38,963) 29,203 (9,760) (39,583) 29,818 (9,765) Interest on equity (58,941) - (58,941) (58,941) - (58,941) Retained earnings 197,041-197,041 197,041-197,041 3. Risk management The main risk factors the Company and its subsidiaries are exposed to are financial and operating risks, including market, foreign exchange, interest rate, credit and liquidity risks. These risks are inherent to the Company s activities and are managed through internal controls and policies. The policies set forth are supervised and monitored through monthly managerial reports. Fair value hierarchy The assumptions used by the Company to determine the hierarchy and disclose the fair values of financial instruments are: Level 1: prices quoted in active markets for identical assets or liabilities; Level 2: other techniques for which all inputs which have a significant impact on the recorded fair value are observable, either directly or indirectly; Page 17 of 53

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that is not based on observable market data. a) Accounting classification and fair values Financial assets Level 1 Level 2 Level 3 Total Cash equivalents and marketable securities 1,438 888,331-889,769 Derivative financial instruments - 225-225 Financial liabilities Financing and debentures - (1,372,903) - (1,372,903) Confirming operation - (3,756) - (3,756) Finance lease - (6,964) - (6,964) On September 1,438 (495,067) - (493,629) On December 31, 2017 1,264 (391,716) - (390,430) Given the nature of the balances, we assume that the fair value of the Company s financial instruments is close to the carrying amount. The comparison between the recorded amounts and the fair values did not show differences material enough to be disclosed. b) Capital management The objectives of capital management are to safeguard the continuous return to the Company s shareholders and benefits to other stakeholders, and maintain an ideal capital structure to reduce this cost. In order to maintain or adjust its capital structure, Grupo Fleury can review the dividend payment policy, return capital to shareholders, buy back treasury shares, issue new shares or sell assets to reduce the indebtedness level. Grupo Fleury monitors its capital based on the consolidated financial leverage ratio, which corresponds to net debt divided by equity. Net debt, in turn, corresponds to total borrowings and financing and accounts payable from company acquisitions, as disclosed in the consolidated statement of financial position, less cash and cash equivalents and short-term investments. Financial leverage ratio 9/30/2018 12/31/2017 Financing and debentures 1,372,903 1,054,924 Confirming operation 3,756 - Accounts payable from acquisitions 45,664 14,655 Cash and cash equivalents (130,335) (337,544) Short-term investments (marketable securities) (759,434) (334,286) Page 18 of 53

Net debt 532,554 397,749 Equity 1,727,197 1,706,528 Financial leverage ratio 0.31 0.23 c) Financial and market risks Exchange rate risk The Company and its subsidiaries have trade receivables and trade payables denominated in foreign currency (mainly in U.S. dollars). The risk related to these assets and liabilities arises from the possibility of the Company and its subsidiaries incurring losses due to exchange rate variations. On September, liabilities in foreign currency exposed to this type of risk accounted for 0.08% of total consolidated current liabilities. Grupo Fleury has assets in foreign currency (trade receivables), equivalent to 0.17% of total consolidated accounts receivable on September, which contribute to reduce its exposure to trade payables contracted in foreign currency. The Parent Company contracted derivative financial instruments to hedge against exchange rate fluctuations when acquiring products and services in foreign currency. Below, the Company s net exposure on September (US$1.00 - R$4.0033) and 2017 (US$1.00 - R$3.3074): 9/30/2018 12/31/2017 US$ 000 R$ 000 US$ 000 R$ 000 Trade receivables 234 936 141 466 Trade payables (141) (566) (261) (863) Derivative financial instruments (Note 6) 56 225 5 17 Net exposure 149 595 (115) (380) Interest rate risk The Company has financing in domestic currency subject to interest rates pegged to indices, including the CDI interbank rate, as well as balances of updated taxes paid in installments indexed to the benchmark interest rate (SELIC). The risk inherent in these liabilities arises from the possibility of fluctuations in these rates with an impact on cash flows. The Company and its subsidiaries do not have derivative contracts to hedge this risk because they believe that the risk is mitigated by the existence of assets indexed to the CDI (financial investments). Page 19 of 53

Credit risk Credit risk is the risk that a business counterparty may fail to comply with an obligation set forth in a financial instrument or customer agreement, resulting in a financial loss. Grupo Fleury is exposed to credit risk in its operating activities, which is reflected in the statement of financial position under Trade receivables. At the end of each reporting date, the Company analyzes changes in its clients credit risk in order to check default possibilities that would reduce the amount receivable. Considering the Company s operating segment and business model, it concentrates receivables in specific client groups and, based on the historical analysis of losses of said groups, pursuant to CPC 48, the Company records a provision for estimated losses with a corresponding entry in Other operating expenses, in the statement of income. The purpose of this calculation is to represent the Company s actual receivable amount and the maximum loss per credit risk. Additionally, the Company constantly analyzes each client s economic-financial situation, and adjusts limits or enters into specific agreements in more risky cases. The Company and its subsidiaries are also subject to credit risks related to their operations with financial institutions, represented by bank deposits, financial investments and derivative instruments. In Management s opinion, the risk is low since these operations are carried out with top-tier banks and there are treasury policies with specific limits for the allocation of funds. Liquidity risk Grupo Fleury s cash flow estimate is carried out by the Finance Department. This area monitors the continuous estimates of Grupo Fleury s liquidity requirements to ensure it has sufficient funds to meet its operating needs. It also maintains enough free space available in its credit lines at any time, so that Grupo Fleury is in compliance with the limits and covenants of financing and debentures (when applicable) in all its credit lines. This estimate takes into consideration the Group s debt financing plans, compliance with covenants and internal balance sheet ratio targets and, if applicable, legal or external regulatory requirements, such as currency restrictions. The surplus cash maintained by the operating entities, in addition to the balance required to manage working capital, is used in investments with proper maturities or with liquidity sufficient to provide the necessary margin determined by the abovementioned estimates. The table below analyzes Grupo Fleury s liabilities and financial instruments by maturity date, corresponding to the period remaining in the statement of financial position until the contractual maturity date. The amounts disclosed represent the undiscounted cash flows contracted and, therefore, cannot be reconciled with the carrying amounts. Page 20 of 53

On September Carrying Contracted Less than Between 1 and Between 2 and More than amount amount 1 year 2 years 5 years 5 years Debentures 1,260,039 1,550,537 344,812 241,546 964,179 - Financing 112,864 122,753 33,296 31,964 57,412 81 Confirming operation 3,756 3,756 3,756 - - - Finance lease 6,964 15,431 1,352 6,758 7,321 - Trade payables 162,032 162,032 162,032 - - - Accounts payable company 45,664 55,569 19,853 3,504 32,212 - acquisition Other payables 850 850 850 - - - Policy on the use of derivative financial instruments Grupo Fleury maintains a policy to contract derivative financial instruments in order to manage related risks and ensure that these instruments are accurately recorded in its financial statements. The Company and its subsidiaries do not contract derivative instruments for speculation in the financial market and no margin is given as guarantee in the existing contracts. The amounts are calculated based on models and quotations available in the market, which consider current or future market conditions and gross amounts, before taxes. Due to variations in market rates, these amounts can change until the maturity or early settlement of the transactions. The fair value of these instruments on the date of the financial statements by counterparty is recorded under Derivative financial instruments (Note 6). d) Management of operating risks In accordance with the Brazilian Institute of Corporate Governance (IBGC), operating risk is associated with the possibility of losses (of production, assets, customers, revenues) resulting from flaws, deficiencies or inadequacies of internal processes, people and systems, as well as from external events including natural disasters, frauds, strikes and terrorist attacks. Operating risks usually reduce, degrade or fully or partially interrupt activities and have a negative impact on the Company s reputation, in addition to potentially generating contractual, regulatory and environmental liabilities. With the aim of properly managing its operating risks, Grupo Fleury has striven to establish a governance structure that involves the Senior Management, including the structuring of the Risk Management and Internal Audit departments and ensuring the involvement of the entire leadership positions in implementing initiatives to reduce the Company s exposure to this type of risk, ensuring this commitment through incentives suitable to the organization s reality. The main initiatives carried out by the Company to properly manage operating risks include: Page 21 of 53

a) Biannual cycle of internal audit, covering the Company s main processes; b) Mapping and documentation of internal controls and risks; c) Internal procedures and policies; d) Periodic review of the risk portfolio; e) Monitoring of internal controls; f) Business continuity plans; g) Training of employees and third parties; h) Clear definition of scopes; and i) Implementation of initiatives to reduce exposure to risks, including the contracting of insurance, when applicable. All these measures are monitored and periodically reported to the Audit and Risk Management Committee established by Grupo Fleury s Board of Directors, which instructs and oversees Management during this process. e) Environmental risk The Company implements the following procedures in order to mitigate socio-environmental risks: Waste: Risks related to potential inappropriate disposal of waste generated by operations. In order to mitigate that, Fleury created a waste management system based on legal requirements and voluntary commitments assumed by the Company. The program includes the implementation of work policies and instructions focused on the issue, the setting of annual targets to reduce waste generation, training programs and campaigns to raise employees awareness and continuous monitoring of disposal processes through indicators and based on internal audits. Natural resources: Possible risks associated with reduced availability of natural resources. In this regard, the Company sets annual targets to reduce water and electricity consumption and implement employee continuing education programs and eco-efficiency measures designed to reduce the consumption of these resources, including the search for technology solutions to reduce water consumption and diversification of the Group s energy matrix. The Company s climate change program reinforces these initiatives. Suppliers: In order to reduce supply chain risks, Grupo Fleury has defined socio-environmental and compliance criteria to qualify and evaluate suppliers, including the adoption of evaluation surveys and the search for legal documentation. Moreover, suppliers are required to sign the Citizenship and Sustainability agreement and the Anti-corruption attachment when they are contracted. The sustainability and compliance performance of critical suppliers is monitored through the Program of Excellence in Supply Chain Relationship (PERC). f) Statement of sensitivity analysis Sensitivity analysis for changes in exchange rate The Finance Department periodically assesses the risk of exposure to variations in the U.S. dollar. Page 22 of 53

In order to calculate the probable scenario, the Company used the exchange rate at the closing of this interim financial information (US$1.00 R$4.0033). These instruments are already recorded at fair value through profit or loss (probable scenario) and, therefore, there are no effects for this scenario. In the Possible and Remote scenarios, the exchange rate was increased by 25% and 50%, respectively, before taxes: Possible Remote Maturity Risk (25%) (50%) Trade receivables 2018 US$ depreciation 187 156 Trade payables 2018 US$ appreciation (113) (94) Derivative financial instruments 2018 US$ depreciation 45 38 Net effect 119 100 Sensitivity analysis for changes in interest rate In order to calculate the probable scenario, the Company used the reference rates obtained from the BM&FBOVESPA on September. The Possible and Remote scenarios consider increases of 25% and 50%, respectively. The results, in nominal amounts, are as follows, and debenture interest expenses are calculated until the end of each indexed contract. Probable Possible Remote CDI (p.a.) 6.39% 6.39% 6.39% +25% +50% Accounting Probable Possible Remote balance Financial investments classified as Cash and 4,118 128,897 8,237 2,059 cash equivalents Financial investments classified as Marketable 24,264 759,434 48,528 12,132 securities Debentures (1,260,039) (80,517) (20,129) (40,258) Net exposure in CDI (371,708) (23,752) (5,938) (11,876) 4. Cash and cash equivalents Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Cash and banks 947 1,090 1,438 1,264 Cash equivalents: Fixed term deposits (i) 24,292 94,617 24,353 94,682 Repurchase agreements (ii) 102,625 241,446 104,544 241,581 Capitalization bonds - - - 17 Page 23 of 53

126,917 336,063 128,897 336,280 127,864 337,153 130,335 337,544 (i) Refer to Financial bills. The average profitability of these operations was 99.4% in the first nine months of 2018 and 105.1% in 2017. (ii) On September and December 31, 2017, the automatic investments were remunerated at an average weighted rate of 20% of the CDI, while the repurchase agreements were remunerated at an average rate of 99.3% in the first nine months of 2018 and 96.4% in 2017. 5. Marketable securities Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Government bonds (i) 162,089 332,139 162,494 332,394 Fund quotas indexed to the DI rate (ii) 557,775-595,057 - Secured short-term investments 1,883 1,892 1,883 1,892 721,747 334,031 759,434 334,286 (i) Refer to exclusive investments funds in Financial Treasury Bills with average profitability of 100.6% in the first nine months of 2018 (102.4% in 2017). (ii) Refer to Fund quotas indexed to the DI rate, remunerated at an average weighted rate of 99.6% of the CDI in the first nine months of 2018. Short-term investments balance activity schedule (*) Parent Company 9/30/2018 9/30/2017 9/30/2018 9/30/2017 Opening balance 670,094 399,804 670,566 403,473 Investment 1,551,574 904,713 1,625,948 914,616 Acquisition of control IRN - - 18,523 - Earnings 31,822 33,324 32,884 34,265 Redemption (1,404,826) (860,546) (1,459,590) (870,505) 848,664 477,295 888,331 481,849 (*) Fixed term deposits, repurchase agreements, government bonds and other financial investments classified as cash and cash equivalents and marketable securities. 6. Derivative financial instruments Parent Company and Pursuant to the Treasury policy, the Parent Company contracts derivative financial instruments to cover future disbursements with outsourced services and medical equipment. Page 24 of 53

The contracted operations effective in the period ended September are as follows. Type Nominal amount (US$ 000) Currency Counterparty Maturity Contracted rate (R$) (Liability)/Asset 9/30/2018 NDF 471 US$ Itaú 12/28/2018 3.9292 64 NDF 92 US$ Santander 12/28/2018 3.3771 62 NDF 151 US$ Santander 12/28/2018 4.0381 4 NDF 138 US$ Santander 3/28/2019 4.0709 4 NDF 378 US$ Votorantim 3/28/2019 3.9605 50 NDF 190 US$ Itaú 6/28/2019 4.1080 6 NDF 209 US$ Itaú 6/28/2019 3.9998 28 NDF 240 US$ Itaú 9/30/2019 4.1540 7 Total 1,869 225 7. Trade receivables a) Balance breakdown Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Billed amounts 475,582 426,657 480,362 428,824 Amounts to be billed 89,187 95,379 93,602 102,630 564,769 522,036 573,964 531,454 Estimated losses with disallowances (1,827) (1,390) (1,857) (1,390) Estimated losses with disallowances and doubtful accounts (21,043) (17,823) (21,496) (17,823) (22,870) (19,213) (23,353) (19,213) Total receivable 541,899 502,823 550,611 512,241 The aging list of trade receivables is as follows: Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Current 496,479 455,767 505,802 464,596 Past due: Up to 120 days 37,826 35,298 37,663 35,884 121 to 360 days 21,394 24,845 21,428 24,848 Over 361 days 9,070 6,126 9,071 6,126 564,769 522,036 573,964 531,454 Page 25 of 53

Changes of estimated losses with disallowances and doubtful accounts Parent Company 9/30/2018 9/30/2017 9/30/2018 9/30/2017 Balance at the beginning of the period (19,213) (41,610) (19,213) (41,648) Write-off of uncollectible instruments 26,933 53,089 26,957 53,089 Addition due to acquisition of subsidiary - - (459) - Additions of disallowances and doubtful accounts (Notes 28 and 31) (30,590) (34,471) (30,638) (34,433) Balance at the end of the period (22,870) (22,992) (23,353) (22,992) The Company and its subsidiaries have a certain degree of concentration in their customer portfolio. On September 30, 2018, the six main customers accounted for 49.6% of the total portfolio (49.1% on December 31, 2017). 8. Inventories Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Diagnostic kits 11,200 11,732 11,802 11,732 Collection and nursing material 5,330 4,953 5,419 4,953 Auxiliary laboratory materials 2,749 2,810 2,751 2,856 Administrative, promotional and other types of material 1,980 1,992 2,011 2,004 21,259 21,487 21,983 21,545 9. Taxes recoverable Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Withholding income tax (IRPJ) 12,853 14,949 13,525 14,962 Social Integration Program Tax on Revenue (PIS) and Social Security Financing Tax on 8,341 7,406 8,642 7,514 Revenue (COFINS) Social security tax (INSS) 5,114 1,091 5,114 1,091 Tax on services (ISS) 3,604 3,461 3,605 3,461 29,912 26,907 30,886 27,028 Page 26 of 53

10. Judicial deposits Noncurrent assets On September, judicial deposits totaled R$48,232 at the Parent Company (R$47,419 on December 31, 2017) and R$48,365 in the (R$47,521 on December 31, 2017) and refer to lawsuits classified as remote or possible loss by the Company s legal counsel and for which, therefore, a provision for contingencies has not been recorded. Among these claims is an amount of R$11,269 related to ICMS tax levied on equipment imports (Note 23). Noncurrent liabilities Judicial deposits referring to lawsuits considered as probable loss are recorded under noncurrent liabilities, reducing the balance of the related provision by R$7,556 on September (R$6,810 on December 31, 2017). Judicial deposits also included R$979 related to ISS tax described in Note 20, in the Other item, net of the obligation in the same amount. 11. Receivables Parent Company and 9/30/2018 12/31/2017 Balance receivable for the sale of the investment in Cruzeiro do Sul 8,280 16,548 8,280 16,548 Current 4,752 3,854 Noncurrent 3,528 12,694 12. Investments Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Fleury CPMA (direct subsidiary) 142,282 47,022 - - Papaiz (joint venture) - - 10,316 9,499 Serdil (indirect subsidiary) IRN (indirect subsidiary) - - - 295 1,652-254 - 142,282 47,022 10,865 11,151 Page 27 of 53

Other 1,532 145 1,532 145 143,814 47,167 12,397 11,296 The consolidation process of Serdil and IRN is based on the subsidiaries balance with a 30-day lag, a procedure provided for in article 10 of CVM Normative Instruction. This procedure implies that some intercompany balances are not eliminated. Subsidiary/joint ventures Reference date Number of shares of capital stock % of interest in paid-up capital Paid-up capital Equity Profit (loss) for the period Fleury CPMA 9/30/2018 187,663 100% 187,663 140,931 1,279 12/31/2017 81,007 100% 81,007 45,671 5,198 Serdil 9/30/2018 4,736 100% 4,736 8,174 (1,483) 12/31/2017 9,974 100% 968 1,983 n/a Papaiz 9/30/2018 1,466 51% 1,466 4,463 817 12/31/2017 2,875 51% 2,875 7,149 1,830 IRN 9/30/2018 7,000 100% 7,000 15,406 3,073 12/31/2017 - - - - - Cardionuclear 9/30/2018 250 100% 250 2,099 74 12/31/2017 - - - - - Radiodonto Natal 9/30/2018 10 100% 10 (5) 17 12/31/2017 - - - - - Parent Company Investees Changes in investment balances Balance on 12/31/2017 Acquisition Paid-up capital Equity in the earnings (losses) of subsidiaries Other changes Balance on 9/30/2018 Fleury S.A. Fleury CPMA 47,022-92,500 1,279 1,481 142,282 Fleury S.A. Other 145 1,387 - - - 1,532 Subtotal Parent Company 47,167 1,387 92,500 1,279 1,481 143,814 Fleury CPMA Papaiz 9,499 - - 817-10,316 Page 28 of 53

Fleury CPMA Serdil 1,652 - - - (1,357) 295 Fleury CPMA IRN - - - - 254 254 Fleury S.A. Other (a) 145 1,387 - - - 1,532 Subtotal 11,296 1,387-817 (1,103) 12,397 (a) Investment in the startup Qure, jointly with Grupo Sabin. 13. Property and equipment Average annual depreciation rate % Cost Parent Company 9/30/2018 12/31/2017 Accumulated depreciation Net balance Net balance Machinery and equipment 8 555,755 (268,431) 287,324 263,390 Leasehold improvements 20 266,425 (102,915) 163,510 162,564 Facilities 10 266,855 (168,897) 97,958 112,946 Construction in progress (a) - 54,542-54,542 17,499 Properties 2 32,915 (5,460) 27,455 27,867 IT equipment 20 79,476 (58,533) 20,943 21,534 Land - 16,123-16,123 16,123 Furniture and fixtures 10 46,886 (34,412) 12,474 11,381 1,318,977 (638,648) 680,329 633,304 Average annual depreciation rate % Cost 9/30/2018 12/31/2017 Accumulated depreciation Net balance Net balance Machinery and equipment 8 608,683 (301,546) 307,137 270,520 Leasehold improvements 20 268,386 (102,943) 165,443 162,564 Facilities 10 270,217 (170,135) 100,082 114,167 Properties 2 32,915 (5,460) 27,455 27,867 Construction in progress (a) - 54,648-54,648 17,499 IT equipment 20 82,192 (60,876) 21,316 21,651 Land - 16,123-16,123 16,123 Furniture and fixtures 10 49,346 (36,284) 13,062 11,529 1,382,510 (677,244) 705,266 641,920 (a) Mainly focused on expansion and improvement of units and technical areas. Changes in property and equipment are shown below: Page 29 of 53

Balance on 12/31/2017 Changes - Parent Company Net Additions writeoffs Depreciation Reclassifications/ transfers Balance on 9/30/2018 Machinery and equipment 263,390 47,825 (577) (34,557) 11,243 287,324 Leasehold improvements 162,564 24,322 (151) (31,167) 7,942 163,510 Facilities 112,946 2,755 (279) (18,378) 914 97,958 Construction in progress 17,499 61,485 - - (24,442) 54,542 Properties 27,867 - - (412) - 27,455 IT equipment 21,534 4,282 (9) (5,608) 744 20,943 Land 16,123 - - - - 16,123 Furniture and fixtures 11,381 1,253 (51) (2,045) 1,936 12,474 633,304 141,922 (1,067) (92,167) (1,663) 680,329 Balance on 12/31/2017 Acquisition of subsidiary (b) Goodwill IRN Changes - Additions Net write-offs Depreciation Reclassifications/ transfers Balance on 9/30/2018 Machinery and equipment 270,520 9,816 3,307 49,197 (577) (37,228) 12,102 307,137 Leasehold improvements 162,564 - - 26,282 (151) (31,194) 7,942 165,443 Facilities 114,167 22 18 3,747 (279) (18,437) 844 100,082 Properties 27,867 - - - - (412) - 27,455 Construction in progress 17,499 - - 61,592 - - (24,443) 54,648 IT equipment 21,651 66 (334) 4,826 (9) (5,650) 766 21,316 Land 16,123 - - - - - 16,123 Furniture and fixtures 11,529 305 141 1,413 (51) (2,115) 1,840 13,062 641,920 10,209 3,132 147,057 (1,067) (95,036) (949) 705,266 (b) Acquisition of the control of Grupo IRN. See Note 2. Changes Parent Company and Balance on 12/31/2016 Additions Net write-offs Depreciation Reclassifications/ transfers Balance on 9/30/2017 Machinery and equipment 181,250 49,209 (177) (29,643) 18,852 219,491 Leasehold improvements 56,175 24,225 (8) (13,688) 61,811 128,515 Facilities 131,529 3,834 (147) (18,146) 2,228 119,298 Construction in progress 34,509 82,931 - - (86,324) 31,116 Properties 23,445 - - (350) - 23,095 IT equipment 17,383 2,305 - (4,846) 2,012 16,854 Land 13,637 - - - - 13,637 Furniture and fixtures 12,481 1,017 (2,454) (2,038) 1,430 10,436 470,409 163,521 (2,786) (68,711) 9 562,442 Page 30 of 53

14. Intangible assets Average annual amortization rate - % Cost Parent Company 9/30/2018 12/31/2017 Accumulated amortization Net balance Net balance Goodwill - 1,342,222 (44,413) 1,297,809 1,297,809 Licenses and software developed/acquired 20 293,391 (164,940) 128,451 132,916 Customer contracts 10 154,387 (108,071) 46,316 57,895 Intangible assets in progress (software and products) - 19,032-19,032 9,625 Trademarks and patents 7 13,226 (7,564) 5,662 6,360 Products internally developed - 3,895-3,895 984 1,826,153 (324,988) 1,501,165 1,505,589 Average annual amortization rate - % Cost 9/30/2018 12/31/2017 Accumulated amortization Net balance Net balance Goodwill - 1,438,722 (44,413) 1,394,309 1,327,985 Licenses and software 295,155 (166,425) 128,730 developed/acquired 20 133,062 Customer contracts 10 156,573 (110,257) 46,316 58,223 Intangible assets in progress 19,486 (software and products) - 19,486-9,625 Trademarks and patents 7 21,208 (9,156) 12,052 7,430 Products internally developed - 3,895-3,895 984 1,935,039 (330,251) 1,604,788 1,537,309 Changes in intangible assets are shown below: Balance on 12/31/2017 Changes Parent Company Additions Amortization Reclassifications/ transfers Balance on 9/30/2018 Goodwill 1,297,809 - - - 1,297,809 Licenses and software developed/acquired 132,916 16,875 (27,360) 6,020 128,451 Customer contracts 57,895 - (11,579) - 46,316 Intangible assets in progress (software and products) 9,625 18,184 - (8,777) 19,032 Trademarks and patents 6,360 - (698) - 5,662 Products internally developed 984 38-2,873 3,895 1,505,589 35,097 (39,637) 116 1,501,165 Page 31 of 53

Balance on 12/31/2017 Acquisition of subsidiary (a) Goodwill IRN Additions Amortization Reclassifications / transfers Balance on 9/30/2018 Goodwill 1,327,985 65,809-515 - - 1,394,309 Licenses and software developed/acquired 133,062 - - 17,138 (27,364) 5,894 128,730 Customer contracts 58,223 - - - (11,907) - 46,316 Intangible assets in progress (software and 9,625 - - 18,637 - (8,776) 19,486 products) Trademarks and patents 7,430-4,952 - (920) 590 12,052 Products internally developed 984 - - 38-2,873 3,895 1,537,309 65,809 4,952 36,328 (40,191) 581 1,604,788 (a) Acquisition of the control of Grupo IRN. See Note 2. Balance on 12/31/2016 Additions Changes Parent Company Reclassification Amortization / transfers Balance on 9/30/2017 Goodwill 1,297,809 - - - 1,297,809 Licenses and software developed/acquired 53,290 6,396 (21,827) 63,627 101,486 Customer contracts 73,334 - (11,579) - 61,755 Intangible assets in progress (software and products) 78,852 24,552 - (64,195) 39,209 Trademarks and patents 7,291 - (698) - 6,593 Products internally developed 449 - - 279 728 1,511,025 30,948 (34,104) (289) 1,507,580 Balance on 12/31/2016 Additions Net writeoffs Changes - Amortization Reclassifications/ transfers Balance on 9/30/2017 Goodwill 1,309,150 - - - - 1,309,150 Licenses and software developed/acquired 53,290 6,396 - (21,827) 63,627 101,486 Customer contracts 74,098 - - (11,906) - 62,192 Intangible assets in progress (software and products) 78,852 24,552 - - (64,195) 39,209 Trademarks and patents 7,885 - - (829) - 7,056 Products internally developed 449 - - - 279 728 1,523,724 30,948 - (34,562) (289) 1,519,821 Page 32 of 53

15. Financing Funding - Funders Domestic currency R$ Charges fixed rate Signature date Contracted amount Accumulated amount paid Final maturity FINEP PROMETHEUS I and II 4.00% p.a. 8/28/2014 155,444 152,444 09/2022 FINEP 2 4.00% p.a. 8/6/2012 10,752 10,752 08/2020 BNDES FINAME 3.55% p.a. 1/31/2013 4,876 4,876 11/2023 Funders Domestic currency R$ 12/31/2017 Incurred interest Changes - Parent Company Interest Principal Release/ paid amortization New transactions 9/30/2018 FINEP PROMETHEUS I 127,052 3,479 (3,525) (20,026) - 106,980 and II FINEP 2 5,298 135 (138) (1,487) - 3,808 Confirming operation (a) - - - - 3,756 3,756 Other loans (LIS) 1,263 - - (1,263) - - 133,613 3,614 (3,663) (22,776) 3,756 114,544 Capitalization cost (b) (1,216) - - 192 - (1,024) 132,397 3,614 (3,663) (22,584) 3,756 113,520 Current 29,922 32,366 Noncurrent 102,475 81,154 Changes - Funders Domestic currency R$ 12/31/2017 Incurred interest Interest paid Principal amortization Release/ New transactions 9/30/2018 FINEP PROMETHEUS I and II 127,052 3,479 (3,525) (20,026) - 106,980 FINEP 2 5,298 135 (138) (1,487) - 3,808 Confirming operation (a) - - - - 3,756 3,756 BNDES FINAME (c) 3,692 103 (102) (593) - 3,100 Other loans 1,384 - - (1,384) - - Working capital 687 - - (687) - - 138,113 3,717 (3,765) (24,177) 3,756 117,644 Capitalization cost (**) (1,216) - - 192 - (1,024) 136,897 3,717 (3,765) (23,985) 3,756 116,620 Current 30,948 33,006 Noncurrent 105,949 83,614 Page 33 of 53

(a) The Company maintains agreements with partner banks in order to structure a factoring operation with its main suppliers, whereby the latter transfer invoice receivables to the bank in exchange of cash advances. The bank, in turn, becomes the creditor of the operation. The Company settles the invoice on the date originally agreed upon with the suppliers and subsequently receives a commission from the bank for said intermediation and confirmation of the invoices payable. Said operation does not change the prices, terms and conditions previously agreed upon with suppliers. This account reduces Trade payables by debiting the Financing line. (b) The capitalization cost corresponds to the R$1,721 disbursed by FINEP to cover inspection and supervision expenses related to the Prometheus I and Prometheus II projects. (c) Acquisition of medical equipment. On September, the noncurrent installments of the financings matured as follows: Parent Company 2019 7,108 7,320 2020 27,767 28,381 2021 to 2023 46,279 47,913 81,154 83,614 FINEP has a clause that requires the Company to ensure the payment of any liability arising from the agreement by issuing a bank guarantee letter in the amount of the entire financing. This clause is indispensable to the signature of the agreement. Certain financings have covenants, including but not limited to the execution or formalization of collateral or personal guarantees, restrictions to the change, transfer or assignment of controlling interest, merger or spin-off without the creditor s prior consent, and the maintenance of financial and liquidity ratios measured every six months. On September, the Company and its subsidiaries complied with all the above mentioned financial ratios, as well as with all the covenants. 16. Debentures The debentures were placed as follows: Issue amount (R$) Number of debentures Final maturity Semi-annual interest Total issued Page 34 of 53

1st Issue Second Series 10,000 30,000 Dec 2018 CDI + 1.20% p.a. 300,000 2nd Issue Single Series 10,000 50,000 Feb 2020 CDI + 0.85% p.a. 500,000 3rd Issue Single Series 10,000 30,000 Nov 2022 CDI + 0.49% p.a. 300,000 4th Issue First Series 10,000 25,000 Apr 2021 CDI + 0.35% p.a. 250,000 4th Issue Second Series 10,000 25,000 Apr 2023 CDI + 0.60% p.a. 250,000 The Company used the amounts raised with the debenture issues to strengthen its working capital, maintain its cash strategy, extend its debt profile and fund its investments and acquisitions in the coming years. The debentures issued are non-convertible and unsecured. 1st Debenture Issue The Company carried out its first debenture issue through a public offering for the distribution of simple debentures with restricted placement efforts, in two series, concluded on December 12, 2011. The First Series, totaling R$150,000, was totally amortized in the respective maturity dates until December 31, 2016. The Second Series was issued to be amortized in three equal and annual installments. The second installment was amortized on December 12, 2017, and the third in 2018, there being no optional early redemption or renegotiation. 2nd Debenture Issue This issue was carried out through a public offering for the distribution of simple debentures with restricted placement efforts, in a single series, concluded on February 19, 2013. The debentures will be/were amortized in three equal and annual installments on February 15, 2018, 2019 and 2020. Payment of remuneration will occur every six months and there are no plans for renegotiation. 3rd Debenture Issue This issue was carried out through a public offering for the distribution of simple debentures with restricted placement efforts, in a single series; the Company issued thirty thousand (30,000) debentures, all registered, book-entry, with nominal unit value of R$10,000, totaling R$300,000. The debentures will mature in five (5) years as of the issue date and will be amortized in two annual installments, 50% of which on November 24, 2021, and 50% on November 24, 2022. 4th Debenture Issue The Company carried out its fourth debenture issue through a public offering for the distribution of simple debentures with restricted placement efforts, in two series, whereby the First series, totaling R$250,000, will be fully amortized on its maturity date, i.e. April 27, 2021. The Second series also totaled R$250,000 and will be fully amortized on its maturity date, i.e. April 27, 2023. Changes in debentures Parent Company and Page 35 of 53

Domestic currency R$ 12/31/2017 Incurred interest Interest paid Principal amortization Release 9/30/2018 1st Issue Second Series 100,374 5,684 (3,777) - - 102,281 2nd Issue Single Series 515,826 19,696 (32,621) (166,667) - 336,234 3rd Issue Single Series 301,827 15,437 (10,098) - - 307,166 4th Issue First Series - 7,043 - - 250,000 257,043 4th Issue Second Series - 7,315 - - 250,000 257,315 918,027 55,175 (46,496) (166,667) 500,000 1,260,039 Current 284,693 293,372 Noncurrent 633,334 966,667 The installments recorded under Noncurrent liabilities on September, mature as follows: Maturity 2nd Issue 3rd Issue 4th Issue 4th Issue Single Series Single Series First Series Second Series 2020 166,667 - - - 166,667 2021-150,000 250,000-400,000 2022-150,000 - - 150,000 2023 - - - 250,000 250,000 166,667 300,000 250,000 250,000 966,667 Covenants The debentures have covenants, and all obligations related to them will mature early if the Company fails to comply with the following financial ratios: (a) Net financial debt/earnings before interest, depreciation and amortization (EBITDA) ratio lower than or equal to 3.0 times and/or; (b) EBITDA/Net financial expense ratio equal to or higher than 1.5 times. On September, the Company and its subsidiaries complied with all the above mentioned financial ratios, as well as with all the covenants. 17. Finance lease The Company signed the built to suit lease agreement of the Santo André II unit for 146 months, restated based on the annual accumulated variation of the IPCA Consumer Price Index. On September, the financial lease liabilities are as follows: Page 36 of 53

Parent Company and Minimum lease payments 9/30/2018 12/31/2017 Less than 1 year 1,352 1,308 Between 1 and 5 years 6,758 6,540 More than 5 years 7,321 7,848 15,431 15,696 (-) Future financial charges (8,467) (8,321) Present value of the minimum payments 6,964 7,375 Current 610 606 Noncurrent 6,354 6,769 18. Trade payables Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Domestic 156,988 145,988 161,466 147,622 Foreign 566 863 566 863 157,554 146,851 162,032 148,485 19. Payroll and related charges Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Provision for vacation and charges 48,679 46,898 49,761 47,204 Provision for Christmas bonus 26,266-26,898 - payable and charges Provision for profit sharing 24,105 32,434 24,105 32,434 Provision for health care and 23,022 3,273 23,100 3,503 others Payroll charges payable 13,534 17,139 13,894 17,213 135,606 99,744 137,758 100,354 20. Taxes and contributions payable Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 REFIS Installment Law 11,941 29,214 39,960 30,423 41,186 PIS/COFINS on revenue 8,366 6,907 8,506 6,982 ISS on revenue 6,134 5,173 6,385 5,368 Page 37 of 53

Other 4,590 821 4,888 1,215 PIS, COFINS and withholding social contribution (CSRF) 1,925 1,940 2,132 2,007 INSS withheld 1,324 1,614 1,365 1,623 Withholding income tax (IRRF) 935 1,011 975 1,032 ISS paid in installments (RJ and SP) 443 652 443 711 Total 52,931 58,078 55,117 60,124 Current 23,941 29,878 24,875 30,575 Noncurrent 28,990 28,200 30,242 29,549 On September, noncurrent installments matured as follows: 2019 1,178 2020 4,673 2021 4,503 2022 4,467 2023 onwards 15,421 30,242 21. Accounts Payable Company acquisition Refer to debt incurred due to acquisition of companies, to be paid in accordance with the contractual terms, which are monthly restated, mainly by the IGP-M published by the Getulio Vargas Foundation (FGV) and the Extended Consumer Price Index (IPCA) published by the IBGE. On March 1, 2018, Grupo Fleury acquired the control of the companies comprising Instituto de Radiologia de Natal and a portion of the acquisition, in the amount of R$32,000, was withheld and will be paid as described in Note 2.1 (d). Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Current 256 244 14,363 1,855 Noncurrent 6,739 6,429 31,301 12,800 6,995 6,673 45,664 14,655 On September, noncurrent installments matured as follows: Page 38 of 53

2019 2,453 2020 2,453 2021 8,798 2022 8,798 Other (*) 8,799 31,301 (*) On September, the maturities of specific installments are subject to final and unappealable decisions. It is, therefore, not possible to estimate payment for the coming years. 22. Income tax and social contribution Deferred Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Tax loss 38,173 136,700 47,321 144,852 Provision for tax, labor and civil risks 36,828 36,870 36,828 36,870 Estimated losses with allowance for doubtful accounts 22,870 19,213 22,870 19,213 Effective rate linearization 4,956-4,956 - Goodwill amortization is non-deductible until 2008 and deductible for tax purposes in future periods 24,782 24,782 24,782 24,782 Provision profit sharing 20,411 32,434 20,411 32,434 Stock option provision and other 53,674 26,303 52,633 24,082 Asset revaluation 35 (26) 35 (26) Net assets acquired from business combinations (14,355) (25,150) (16,224) (25,150) Goodwill amortization effects for tax purposes (a) (1,329,483) (1,324,048) (1,329,483) (1,324,048) Tax base (1,142,109) (1,072,922) (1,135,871) (1,066,991) Deferred income and social contribution taxes at a combined rate of approximately 34% (388,317) (364,793) (386,196) (362,777) Income tax and social contribution - Assets 72,807 107,239 75,895 110,025 Income tax and social contribution - Liabilities (461,124) (472,032) (462,091) (472,802) (a) Goodwill from mergers, mainly Labs Cardiolab. The net balance is recorded under noncurrent liabilities, pursuant to CPC 32. The estimated realization term of the deferred tax asset recorded in the is as follows: 2018 16,219 2019 21,041 2020 38,635 Page 39 of 53

75,895 Current and deferred income tax and social contribution recorded in profit (loss) are reconciled as follows: Parent Company 9/30/2018 9/30/2017 9/30/2018 9/30/2017 Income before income tax and social contribution 372,449 344,692 375,085 345,082 Standard rate 34% 34% 34% 34% Income tax and social contribution expenses standard rate (126,633) (117,195) (127,529) (117,328) Interest on equity Equity in the earnings (losses) of subsidiaries 19,572 435 20,040 822 19,572 278 20,040 377 Effect of effective rate linearization 1,685 6,660 1,685 6,661 Other permanent (additions) exclusions 5,894 963 4,311 1,150 Income tax and social contribution expenses: (99,047) (88,710) (101,683) (89,100) Current (76,173) (34,095) (78,915) (34,632) Deferred (22,874) (54,615) (22,768) (54,468) Effective tax rate - % 26.6% 25.74% 27.1% 25.82% 23. Provision for tax, labor and civil risks The Company is subject to tax, labor and civil risks in the normal course of its operations. Management periodically reviews known contingencies, assesses probable losses and adjusts the respective provision, taking into consideration its legal counsel s assessment and other data available at the end of the reporting periods, such as the nature of the lawsuits and past experience. On September, the provision for tax, labor and civil risks was as follows: Parent Company 9/30/2018 12/31/2017 9/30/2018 12/31/2017 Tax 14,308 15,139 14,308 15,153 Labor 19,529 20,316 19,738 20,722 Civil 2,990 1,415 3,019 1,415 36,827 36,870 37,065 37,290 Page 40 of 53

Judicial deposits (Note 10) (7,556) (6,810) (7,556) (6,810) 29,271 30,060 29,509 30,480 Changes in the provision for tax, labor and civil risks () are as follows: Balance on 12/31/2017 Parent Company Addition/ Reversal* Reclassification/ Payments Monetary restatement Balance on 9/30/2018 Tax 15,153 - (2,196) 33 1,318 14,308 Labor 20,722 (185) 781 (3,313) 1,733 19,738 Civil 1,415-1,484 (39) 159 3,019 37,290 (185) 69 (3,319) 3,210 37,065 Judicial Deposits (6,810) - 761 (375) (1,132) (7,556) 30,480 (185) 830 (3,694) 2,078 29,509 * Former shareholders are liable for part of the lawsuits, which will be refunded to the Company at a rate of 67% and, therefore, are reclassified under Other assets. a) Lawsuits classified as a probable loss, for which provisions were recorded: Tax The main tax matter refers to the challenge related to the exemption of COFINS granted to companies that provide services related to professions regulated by law. Supplementary Law 70/91, which created COFINS, addressed the exemption granted to this type of entity. Law 9,430/96, however, expressly revoked this exemption and required the contribution based on the service providers gross revenue. The Company s legal counsel understands that, since Law 9,430/96 is an ordinary law, it could not have revoked the exemption granted by Supplementary Law 70/91. Nevertheless, given that the Federal Supreme Court has already issued an opinion contrary to said thesis, the Company had a provision to cover risks of R$2,085 on September (R$1,787 on December 31, 2017). Labor and civil lawsuits The Company considers that the provision for labor and civil lawsuits is sufficient to cover expected losses. The Group s legal counsel analyzes lawsuits on a case-by-case basis, classifying the risk of loss in accordance with the guidelines established by the Company in its internal policy. b) Lawsuits classified as possible loss Page 41 of 53

The Company has tax, civil and labor claims that are not provisioned since they are classified as a possible loss by Management and its legal counsel. On September, the consolidated amount was approximately R$541,228 (R$479,810 on December 31, 2017). Tax lawsuits classified as a possible loss amounted to R$291,157 (R$315,975 on December 31, 2017), mainly comprising, in the federal sphere: (i) R$134,827 (R$147,101 on December 31, 2017), mainly related to discussions on exemption from income tax (IRPJ), social contribution (CSLL), social integration program tax on revenue (PIS), social security financing tax on revenue (COFINS) and import PIS/COFINS; (ii) social security contributions totaling R$52,865 (R$62,740 on December 31, 2017); and (iii) sundry federal lawsuits totaling R$5,239 (R$4,627 on December 31, 2017). Regarding state taxes, lawsuits classified as a possible loss amounted to R$28,536 (R$40,473 on December 31, 2017) and mainly refer to state value-added tax (ICMS) on equipment imports. In relation to municipal taxes, lawsuits classified as a possible loss reached R$69,690 (R$61,033 on December 31, 2017) and mainly refer to claims involving tax on services of any kind (ISSQN). In the civil sphere, the Company s lawsuits classified as a possible loss totaled R$43,360 (R$36,480 on December 31, 2017), of which R$12,385 (R$13,156 on December 31, 2017) mainly related to civil liability lawsuits claiming compensation for damages and pain and suffering due to, among others, alleged diagnostic errors or malpractice, and other lawsuits addressing different requests, totaling R$30,975 (R$23,324 on December 31, 2017). Labor lawsuits classified as a possible loss amounted to R$206,711 (R$127,348 on December 31, 2017), of which (i) R$197,747 (R$100,724 on December 31, 2017) refers to labor claims from former employees; (ii) R$8,737 (R$10,421 on December 31, 2017) refers to secondary liability lawsuits filed by employees of companies that render specialized services to the Company on an outsourced basis; and (iii) R$227 (R$16,203 on December 31, 2017) refers to ongoing administrative lawsuits. Also in the labor sphere, the Company was summoned in a public civil action suit pending at the Labor Court of Rio de Janeiro that essentially challenges the legality of hiring specialized medical companies. In addition, the request by the public civil action comprises the payment of R$4,063 for collective pain and suffering. The Company is fighting this lawsuit by proving the legitimacy of its practice in accordance with the applicable laws, being supported by court precedents in favor of hiring legal entities to provide medical services. By the way, the recent decision of the Federal Supreme Court (ADPF 324 and RE 958252, with general repercussion) regarding the lawfulness of outsourcing employees both for the core and related activities supports the Company s defense arguments regarding the legitimacy of hiring medical companies, which may influence the outcome of this lawsuit. In summary, the first instance court denied the claim; this decision was partially overruled by the 1st Region Appellate Labor Court. The Company filed motions for clarification, which were partially granted, and, subsequently, filed an appeal at the Superior Labor Court, which is currently Page 42 of 53

pending trial. The likelihood of success has not changed in the opinion of the legal counsel given Superior Labor Court cases and the recent pronouncement of Federal Supreme Court. Finally, also in the labor sphere, the Company was summoned in a public civil action suit filed by the Labor Prosecution Office of the São Paulo State challenging compliance with the quota reserved for People with Disabilities, pursuant to article 93 of Law 8,213/91. The lawsuit is in the initial stage but, given the favorable case law and the elements that prove the Company s overall active initiatives, not only regarding compliance with the quota, but also the creation of internal policies and initiatives to promote inclusion and diversity as part of a permanent agenda focused on prioritizing social responsibility, the likelihood of success is possible. 24. Operating lease A large share of the properties used in operating activities is leased, with terms and amounts established by agreements effective from four to six years. In the period ended September, the Company s rental expenses totaled R$93,831 (R$87,907 on September 30, 2017). The agreement amounts are monetarily restated after the original maturity date (usually annual). This adjustment is calculated based on the General Market Price Index (IGP-M) variation. The consolidated lease commitments totaled R$447,649 on September (R$432,595 on September 30, 2017). The consolidated position of these commitments is as follows: 2018 31,759 2019 117,402 2020 100,631 2021 80,465 2022 onwards 117,392 447,649 25. Related parties a) Impacts on the statement of income and statement of financial position Parent Company and 9/30/2018 9/30/2017 Rental expenses Transinc Fundo Inv. Imobiliário (a) (6,760) (7,287) Amicabilis Participações e Empreendimentos Ltda. (a) (2,664) (2,526) Harmonikos 32 Participações e Empreendimentos Ltda. (a) (2,028) (1,972) Benefit expenses Companies associated with Bradseg (b) (112,759) (109,891) Page 43 of 53

(124,211) (121,676) Parent Company and 9/30/2018 12/31/2017 Statement of financial position: Assets Bradesco (c) 559,615 331,031 Administrative expenses (d) 1,004 - Liabilities Companies associated with Bradseg (b) (4,614) (4,868) Transinc Fundo Inv. Imobiliário (a) (758) (742) Net balance 555,247 325,421 (a) These property funds have shareholders that are direct and indirect shareholders of the Company (Grupo Fleury). (b) Bradseg, a shareholder with a significant interest in the Company, holds an interest in and/or control of health insurance operators and companies that have a business relationship with the Company. Bradseg also holds an indirect interest in Odontoprev S.A., a dental care provider and parent company of Clidec Participações, partner of Fleury Centro de Procedimentos Médicos Avançados, subsidiary of the Company, in Papaiz Associados. These amounts refer to service agreements, mainly health insurance and food/meal and transportation vouchers, and private pension plans. A group of companies associated with Bradseg is among the Company s main clients. (c) Grupo Fleury holds financial investments and balances in bank accounts in Banco Bradesco. On September 30, 2018, investment operations consisted of an exclusive fund classified as fixed revenue and repurchase agreements, whose yields are shown in Notes 4 and 5. (d) The Company provides administrative and clinical analysis services to Serdil and IRN. Signature of a Built to Suit Agreement for the Construction of a New Technical Area and others On August 17, 2018, Grupo Fleury entered into a non-residential lease agreement with BSP Empreendimentos Imobiliários D127 Ltda. and BSP Empreendimentos Imobiliários S.A, companies controlled by BRADSEG Participações (related party). The property was leased, under the Built to Suit model, in order to house the Company s new Technical Area in the city of São Paulo, as well as patient service centers and administrative offices. BSP Ltda. will be responsible for building the property. After the conclusion of the works and delivery of the property, the lease term agreed upon with the Company will be 244 months, which includes a four-month grace period, and monthly rental of one million, three hundred and forty-one thousand reais (R$1,341,000), annually restated by the IGP-M index. Page 44 of 53

Grupo Fleury s property located in Itaim Bibi will secure the lease and should correspond to at least one hundred and fifty million reais (R$150,000,000). If the market value of the property, on the date of creation of the fiduciary guarantee, is less than R$150,000,000, Grupo Fleury will be required to have a lease surety insurance that covers the difference between the market value of the property in Itaim and the value of the fiduciary guarantee, of R$150,000,000. b) Management compensation For the period ended September, Management compensation included salaries, management fees, benefits, payroll charges, stock options and bonus totaling R$18,250 (R$16,877 on September 30, 2017), which is recorded under General and administrative expenses in the statement of income. The compensation of Executive Officers and Management members did not exceed the maximum limit approved by the Meeting held on April 23, 2018. The provision for employee and Management profit sharing totaled R$23,365 in the period ended September (R$22,153 on September 30, 2017). Pursuant to CPC 33 Employee Benefits, the Company offers post-employment benefits to its Management, comprising private pension and life insurance. 26. Equity a) Share capital On September, the fully paid-in share capital was R$1,439,387, represented by 315,654,796 book-entry, registered common shares with no par value. The net amount of share issue expenses was R$1,416,603. The Company is authorized to increase its share capital, regardless of an amendment to the Bylaws, upon resolution of the Board of Directors, up to the limit of 320,000,000 common shares. On August 1, 2018, the Board of Directors approved a capital increase of R$2,995 through the issue of 342,604 shares to meet the exercise of stock options within the scope of the Company s Stock Option Plan. b) Dividends and interest on equity Shareholders are entitled to 25% of the annual profit, as minimum mandatory dividends, adjusted in accordance with Brazilian Corporation Law. On March 1, 2018, the Board of Directors approved ad referendum the Annual Shareholders Meeting the allocation of net profit for 2017, in the amount of R$320,618, as follows: (a) R$16,031 to the legal reserve; (b) R$100,349 as interest on equity, which was already distributed on July 27, 2017; and (c) R$204,238 (0.6477 per share) as dividends, which was paid on April 2, 2018. Page 45 of 53

On July 26, 2018, the Board of Directors approved ad referendum the Annual Shareholders Meeting the payment of interest on equity of R$57,566 (R$0.18 per share), corresponding to retained profit in the first half of 2018, which was settled on August 15, 2018. 27. Employee benefit Private Pension Plan The Company sponsors a private pension plan which is currently managed by Bradesco Vida e Previdência S.A., whose main purpose is to complement the government pension. This definedcontribution plan is optional for all employees. In the period ended September, the Company contributed R$1,541 (R$1,651 in the period ended September 30, 2017) to this plan, recorded under Cost of services and General and administrative expenses. Stock option plan The Company s Board of Directors is responsible for determining, at each grant, the participants of the plan, as well as the number of shares to be acquired when each option is exercised, the term, the exercise price, payment conditions and other conditions. Under the current plans, no amount is paid or will be paid by the beneficiary when the option is received. The options do not grant voting rights or rights to dividends, until they are effectively exercised. Due to the stock split resolved on by the Extraordinary Shareholders Meeting of June 26, 2017, every one (1) share issued by the Company is now represented by two (2) shares of the same type. (i) 2010 to 2014 Grants The Extraordinary Shareholders Meeting of November 12, 2009, approved the Company s Stock Option Plan, authorizing the grant of stock options to employees selected by the Board of Directors. The options granted under this plan will be limited to 3% of the total shares of the Company s subscribed and paid-in share capital. Each stock option may be converted into one common share of Fleury S.A. upon the exercise of the option, which may occur at any moment, from the date the right is acquired to six years after the grant date, when the options expire. No amount is paid or will be paid by the beneficiary when the option is received. The options do not grant voting rights or rights to dividends, until they are effectively exercised. Participants will have at the most six years to exercise the options, as of the date the options are granted. The exercise price of the options will be based on the weighted average of the trading sessions of the month immediately prior to the signing of the option agreement. Exceptionally for the first grant, the exercise price of the options was equivalent to the price per share established within the scope of the first primary public offering of common shares issued by the Company ( IPO ). Page 46 of 53

(ii) 2016 to 2018 Grants The Extraordinary Shareholders Meeting of July 25, 2016, approved the Company s new Stock Option Plan intended for its executives, management, and employees (beneficiaries). The options granted under this Plan may not exceed, during the term of the Stock Option Plan, the maximum accumulated limit of two point five percent (2.5%) of the total shares of the Company s subscribed and paid-in share capital on this date. In these contexts, 1,773,166 options were granted. Also under this plan, the following stock options were approved: Approval date Number of options Approval May 03, 2017 275,000 options Extraordinary Shareholders Meeting October 25, 2017 150,000 options Board of Directors December 15, 2017 235,000 options Extraordinary Shareholders Meeting March 01, 2018 140,000 options Board of Directors May 10, 2018 375,000 options Board of Directors June 20, 2018 47,000 options Board of Directors Each stock option may be converted into one common share of Fleury S.A. upon exercise of each portion of the option, which may occur at any moment, from the date the right is acquired to two years after the exercise date when the options expire. After exercising each portion of the option and subscribing the respective share, the beneficiaries will only be able to sell or transfer them after six months of the date of subscription. The option can be fully exercised by the beneficiaries within, at least, six years as of the signing of the respective adherence agreement. Each portion of the option can be exercised as follows: (i) 12.5% in the 24th month as of the signing of the adherence agreement; (ii) 25% in the 36th month; (iii) 25% in the 48th month; (iv) 25% in the 60th month; and (v) 12.5% after the end of the 72nd month as of the signing of the adherence agreement. The exercise price of the options will be based on the average closing price of the share in the ninety (90) trading sessions prior to the Board of Directors meeting that will resolve on said grant. The changes in the number of stock options and corresponding weighted average exercise prices are as follows: Balance on 12/31/2017 Granted Expired Grant date October 5, 2014 (5th Grant) July 27, 2016 (1st PN) May 3, 2017 (2nd PN) October 25, 2017 (3rd PN) December 15, 2017 (4th PN) March 1, 2018 (5th PN) May 10, 2018 (6th PN) June 20, 2018 (7th PN) Number of options 507,612 2,871,826 550,000 150,000 235,000 - - - Average exercise 8.76 8.74 20.45 29.22 28.80 price - - - Number of options - - - - - 140,000 375,000 47,000 Average exercise price - - - - - 28.18 27.66 26.54 Number of options (48,420) (130,996) (200,000) - - - - - Page 47 of 53

Exercised Balance on 9/30/2018 Average exercise price 8.86 8.74 20.21 - - - - - Number of options - (342,604) - - - - - - Average exercise price - 8.74 - - - - - - Number of options 459,192 2,398,226 350,000 150,000 235,000 140,000 375,000 47,000 Average exercise price 9.05 8.74 20.45 29.22 28.80 28.18 27.66 26.54 From a total of 4,154,418 existing options on September (2,348,575 options on September 30, 2017), 7,394 options can be exercised (21,536 options on September 30, 2017). On September, the Company recorded pro-rata expenses of R$6,154 under General and administrative expenses (R$6,226 in the period ended September 30, 2017). The stock options outstanding on September, had the following maturities and exercise prices: Date Stock options granted Stock option exercise price** Position on 9/30/2018 Position on 9/30/2017 (**) Period price Period price Number of options Number of options 2018 Grant June 20, 2018 47,000 26.54 47,000 26.54 - - 2018 Grant May 10, 2018 375,000 27.66 375,000 27.66 - - 2018 Grant March 1, 2018 140,000 28.18 140,000 28.18 - - 2017 Grant December 15, 2017 235,000 28.80 235,000 28.80 - - 2017 Grant October 25, 2017 150,000 29.22 150,000 29.22 - - 2017 Grant May 3, 2017 550,000 20.45 350,000 20.45 275,000 40.89 2016 Grant July 27, 2016 3,586,712 8.74 2,398,226 8.74 1,559,442 17.48 2014 Grant October 5, 2014 2,298,670 7.14 459,192 9.05 492,597 17.32 2013 Grant April 30, 2013 2,378,592 10.73 - - 21,534 28.25 2012 Grant May 2, 2012 1,465,492 12.11 - - 2 33.82 4,154,418 2,348,575 ** The price of options will be restated by the IPCA Consumer Price Index variation, except for Grants between 2016 and 2018. On June, the market price of each share was R$21.30 (R$29.47 on September 30, 2017). Options granted between 2011 and 2014 were priced based on the binomial model and significant data included in the fair value pricing model of the stock options granted in the period were as follows: Vesting in 48 months Grant on October 5, 2014 Volatility 28.4% Expected life for the exercise of the options 2 years Page 48 of 53

Risk-free annual interest rate 10.33% Options granted between 2016 and 2018 were priced based on the Black & Scholes model and significant data included in the fair value pricing model of the stock options granted in this period were as follows: June 20, 2018 May 10, 2018 March 1, 2018 Vesting in 48 months - Grant on December 15, 2017 October 25, 2017 May 3, 2017 July 27, 2016 Volatility 30.16% 29.49% 29.38% 28.97% 42.79% 29.12% 28.36% Dividend yield 2.94% 3.22% 3.76% 3.17% 2.93% 3.09% 1.75% Expected life for the exercise of 2 years 2 years 2 years 2 years 2 years 2 years 2 years the options Risk-free annual interest rate 7.59% 7.59% 7.71% 8.20% 8.04% 9.54% 12.70% 28. Revenue from services rendered 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 Parent Company 1/01/2018 to 1/01/2017 to 9/30/2018 9/30/2017 Gross revenue 715,852 663,920 2,119,296 1,945,578 Taxes (43,173) (40,774) (130,056) (119,880) Disallowances (10,268) (10,808) (28,486) (34,471) Rebates (277) (317) (616) (438) Net revenue 662,134 612,021 1,960,138 1,790,789 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2017 to 9/30/2017 Gross revenue 738,460 667,699 2,172,849 1,956,323 Taxes (44,847) (40,988) (133,987) (120,487) Disallowances (10,298) (10,808) (28,534) (34,433) Rebates (279) (317) (619) (438) Net revenue 683,036 615,586 2,009,709 1,800,965 29. Cost of services 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 Parent Company 1/01/2018 to 1/01/2017 to 9/30/2018 9/30/2017 Page 49 of 53

Personnel and medical services (222,692) (216,060) (660,695) (614,811) Rent, occupancy and utility services (130,026) (116,047) (380,059) (339,408) Direct material and exam intermediation (67,038) (59,854) (190,160) (177,700) Depreciation and amortization (32,218) (25,139) (94,759) (71,096) General expenditures (1,797) (2,273) (5,344) (6,664) (453,771) (419,373) (1,331,017) (1,209,679) 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2017 to 9/30/2017 Personnel and medical services (234,130) (218,908) (688,335) (623,123) Rent, occupancy and utility services (134,979) (116,047) (389,033) (339,408) Direct material and exam intermediation (68,652) (59,854) (192,883) (177,700) Depreciation and amortization (34,081) (25,291) (98,030) (71,554) General expenditures (1,858) (2,273) (5,452) (6,665) (473,700) (422,373) (1,373,733) (1,218,450) 30. General and administrative expenses 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 Parent Company 1/01/2018 to 1/01/2018 to 9/30/2018 9/30/2017 Personnel and benefits (40,116) (36,372) (119,790) (108,551) Depreciation and amortization (12,432) (10,646) (37,045) (31,719) Marketing (6,601) (5,857) (16,157) (14,444) Other general and administrative expenses (4,279) (4,107) (11,066) (11,080) Institutional and legal matters (2,196) (2,382) (10,800) (6,735) Properties and utilities (2,926) (3,082) (8,809) (8,477) Third-party services (2,266) (2,245) (7,116) (6,743) IT and telecommunications (1,139) (762) (3,535) (3,445) (71,955) (65,453) (214,318) (191,194) 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2018 to 9/30/2017 Personnel and benefits (40,116) (36,372) (120,190) (108,551) Page 50 of 53

Depreciation and amortization (12,432) (10,646) (37,197) (31,719) Marketing (6,605) (5,857) (16,189) (14,444) Other general and administrative expenses (4,303) (4,132) (11,165) (11,113) Institutional and legal matters (2,196) (2,382) (10,880) (6,735) Properties and utilities (2,926) (3,082) (9,197) (8,477) Third-party services (2,303) (2,245) (7,478) (6,779) IT and telecommunications (1,139) (762) (3,619) (3,445) (72,020) (65,478) (215,915) (191,263) 31. Other operating income (expenses), net 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 Parent Company 1/01/2018 to 1/01/2017 to 9/30/2018 9/30/2017 Result from write-off/sale of assets 399-1,168 (2,794) Other income (expenses) 712 (1,239) (3,341) (4,235) Provision for/losses with insolvent debtor (717) - (2,104) - 394 (1,239) (4,277) (7,029) 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2017 to 9/30/2017 Result from write-off/sale of assets 399-1,168 (2,794) Other income (expenses) (327) (1,244) (4,062) (4,240) Provision for/losses with insolvent debtor (708) - (2,325) - (636) (1,244) (5,219) (7,034) 32. Financial result 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 Parent Company 1/01/2017 to 9/30/2017 Financial income: Income from financial investments - securities 11,407 3,214 21,307 9,553 Income from financial investments 2,170 7,312 10,515 23,771 Monetary restatement of taxes and judicial 2,069 1,476 3,935 5,239 deposits Derivative financial instruments 574 31 1,092 182 Page 51 of 53

Exchange variation and others 257 145 437 364 PIS/COFINS on financial income (730) (560) (1,669) (1,805) 15,747 11,618 35,617 37,304 Financial expenses: Interest on debentures (21,777) (17,774) (55,175) (60,955) Interest on financing and other interest (1,480) (1,543) (3,991) (3,882) Exchange variation and others (733) (327) (3,448) (1,055) Monetary restatement of provision for tax, (1,174) (717) (3,210) (2,593) labor and civil risks Financial fees (777) (1,285) (2,725) (2.915) Monetary restatement of payments in (493) (979) (2,202) (6,365) installments and accounts payable company acquisition Derivative financial instruments (320) (268) (451) (681) (26,754) (22,893) (71,202) (78,446) Net financial result (11,007) (11,275) (35,585) (41,142) 7/01/2018 to 9/30/2018 7/01/2017 to 9/30/2017 1/01/2018 to 9/30/2018 1/01/2017 to 9/30/2017 Financial income: Income from financial investments - securities 11,907 3,244 22,233 9,592 Income from financial investments 2,389 7,601 10,651 24,673 Monetary restatement of taxes and judicial 2,056 1,480 3,922 5,262 deposits Derivative financial instruments 574 31 1,092 182 Exchange variation and others 261 145 478 364 PIS/COFINS on financial income (763) (566) (1,738) (1,820) 16,424 11,935 36,638 38,253 Financial expenses: Interest on debentures (21,777) (17,774) (55,175) (60,955) Interest on financing and other interest (1,515) (1,543) (4,118) (3,882) Exchange variation and others (876) (525) (4,003) (1,636) Monetary restatement of taxes and accounts (1,199) (979) (3,736) (6,365) payable Monetary restatement of provision for tax, (1,174) (1,285) (3,210) (2,915) labor and civil risks Financial fees (780) (717) (2,728) (2,593) Derivative financial instruments (320) (268) (451) (681) (27,641) (23,091) (73,421) (79,027) Net financial result (11,217) (11,156) (36,783) (40.774) Page 52 of 53

33. Earnings per share Basic earnings per share Basic earnings per share are calculated by dividing the profit attributable to the Company s shareholders by the weighted average number of common shares issued in the period, excluding common shares acquired by the Company and held as treasury shares. 9/30/2018 9/30/2017 Profit attributable to the Company s shareholders 273,402 255,982 Weighted average number of common shares issued/outstanding 314,993,891 314,540,706 Basic earnings per share - R$ 0.87 0.81 Diluted earnings per share Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares to assume the conversion of all diluted potential common shares. The Company had outstanding dilutive potential common shares in the period, related to the Company s Stock Option Plan, as follows: 9/30/2018 9/30/2017 Profit attributable to the Company s shareholders 273,402 255,982 Weighted average number of outstanding common shares 314,993,891 314,540,706 (+) Adjustments due to stock options 7,673,325 5,299,799 (=) Weighted average number of common shares for diluted earnings per share 322,667,216 319,840,505 Diluted earnings per share - R$ 0.85 0.79 34. Segment reporting Grupo Fleury s Management carries out analyses based on three significant business segments: Diagnostic Medicine, Integrated Medicine and Dental. The segments presented in the financial statements are strategic business units that offer different products and services. Diagnostic Medicine Period ended 9/30/2018 Period ended 9/30/2017 Integrated Diagnostic Integrated Dental Dental Medicine Medicine Medicine Net revenue 1,683,083 326,310 316 2,009,709 1,504,678 296,287-1,800,965 Page 53 of 53

EBITDA 493,110 53,142 27 546,278 439,310 48,711-488,021 Equity in the earnings of joint venture - - 817 817 - - 1,108 1,108 Depreciation and - - - - - - (135,227) amortization (103,273) Financial result - - - (36,783) - - - (40,774) Income before income - - - - - - 375,085 taxes 345,082 Assets and liabilities by reportable segment are not being presented, in line with CPC 22, given that this information is not regularly presented to the main managers of the operations. Pursuant to accounting standard CPC 19 (R2) - Joint Arrangements, the indirect subsidiary Papaiz is accounted for by the equity accounting method because it is jointly controlled. Dental operations are broken down as follows: 9/30/2018 9/30/2017 Net revenue 9,114 7,903 EBITDA 2,074 1,957 Depreciation and amortization (466) (349) Financial result (428) (250) Income before taxes 1,180 1,358 Income tax and social contribution (289) (250) Profit 891 1,108 35. Insurance The Company has the policy to contract insurance for possible risks related to its assets, loss of profit and/or liability in amounts sufficient to cover possible losses, considering the nature of its activities and in accordance with the assessment of Management and its specialized consultants. The Parent Company s net insurance premium for the policies in effect on September, totaled R$733, while the came to R$738. The agreements are in effect until April 19, 2019. The maximum amounts insured by the main insurance on September were as follows: Operating risks R$590,700 Civil liability R$105,000 International transport - imports US$ ( 000) 650 36. Events after the reporting period Wind up of the Radiodonto operation Page 54 of 53

On October 12, 2018, Radiodonto, a subsidiary of Instituto de Radiologia de Natal acquired on March 1, 2018, was wound up. As balances were immaterial, they will not be presented as a discontinued operation. The recent balances calculated at the end of the reporting period are as follows: Total assets: R$141 Property and equipment: R$23 Equity: R$5 Net income (Jan to Aug 2018): R$17 *** Carlos Alberto Iwata Marinelli CEO Fernando Augusto Rodrigues Leão Filho Chief Executive Finance and Legal Officer Gisele Schneider Technical manager TCRC 1SP304488 Page 55 of 53

BOARD OF EXECUTIVE DIRECTORS DECLARATION ABOUT FINANCIAL STATEMENTS The Executive Directors of Fleury S.A. ("Company"), pursuant to item VI of Article 25 of CVM Instruction 480 of December 7 th, 2009, declare that they reviewed, discussed and agreed with the Company's financial statements for the period ended on September, authorizing the completion on this date. São Paulo, October 24 th, 2018. Board of Executive Directors Carlos Alberto Iwata Marinelli Chief Executive Officer Fernando Augusto Rodrigues Leão Filho Chief Financial, Investor Relations and Legal Officer Paulo Pedote Regional Brands Business Officer Jeane Mike Tsutsui Fleury Brand Officer José Roberto Araujo da Silva Commercial and B2B Business Officer Galeno Augusto Jung Strategy, Marketing and Innovation Officer Claudio Almeida Prado Operations Support Officer Edgar Gil Rizzatti Medical, Technical and Process Officer

BOARD OF EXECUTIVE DIRECTORS DECLARATION ABOUT INDEPENDENT AUDITOR'S REPORT The Executive Officers of Fleury S.A. ("Company"), in accordance with item V of Article 25 of CVM Instruction 480 of December 7 th, 2009, declare that they reviewed, discussed and agreed with the opinions expressed in the independent auditors' report on the Company's financial statements for the period ended September, authorizing the completion on this date. São Paulo, October 24 th, 2018. Board of Executive Directors Carlos Alberto Iwata Marinelli Chief Executive Officer Fernando Augusto Rodrigues Leão Filho Chief Financial, Investor Relations and Legal Officer Paulo Pedote Regional Brands Business Officer Jeane Mike Tsutsui Fleury Brand Officer José Roberto Araujo da Silva Commercial and B2B Business Officer Galeno Augusto Jung Strategy, Marketing and Innovation Officer Claudio Almeida Prado Operations Support Officer Edgar Gil Rizzatti Medical, Technical and Process Officer